MEI Pharma Announces Planned Chief Financial Officer Transition

Brian Drazba, Chief Financial Officer of MEI Pharma, to Retire at the End of 2021

PR Newswire

SAN DIEGO, Aug. 5, 2021 /PRNewswire/ — MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that Brian Drazba, chief financial officer of MEI Pharma, has informed the company that he is retiring. Mr. Drazba, an industry veteran who has overseen financial operations since joining in April 2017, will continue to serve in his current role and provide transitional support through the end of 2021.

“On behalf of the entire MEI team, I would like to thank Brian for his contributions and leadership over the last four years,” said Daniel P. Gold, Ph.D., president and chief executive officer of MEI Pharma. “Brian has played a prominent role in MEI’s growth over the years and in building and strengthening the company’s financial infrastructure. I personally wish Brian all the best in his next chapter.”

Ahead of Mr. Drazba’s retirement, the company has initiated a search for a new chief financial officer.  

About MEI Pharma
MEI Pharma, Inc. (Nasdaq: MEIP) is a late-stage pharmaceutical company focused on developing potential new therapies for cancer. MEI Pharma’s portfolio of drug candidates contains four clinical-stage assets, including zandelisib, currently in multiple ongoing clinical trials which may support marketing approvals with the U.S. Food and Drug Administration and other regulatory authorities globally. Each of MEI Pharma’s pipeline candidates leverages a different mechanism of action with the objective of developing therapeutic options that are: (1) differentiated, (2) address unmet medical needs and (3) deliver improved benefit to patients either as standalone treatments or in combination with other therapeutic options. For more information, please visit www.meipharma.com. Follow us on Twitter @MEI_Pharma and on LinkedIn.

Forward-Looking Statements
Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical studies and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management’s current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties or differences in interpretation in clinical trial results; the impact of the COVID-19 pandemic on our industry and individual companies, including on our counterparties, the supply chain, the execution of our clinical development programs, our access to financing and the allocation of government resources; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/mei-pharma-announces-planned-chief-financial-officer-transition-301349750.html

SOURCE MEI Pharma, Inc.

ViewRay Reports Second Quarter 2021 Results

PR Newswire

CLEVELAND, Aug. 5, 2021 /PRNewswire/ — ViewRay, Inc. (Nasdaq: VRAY) (the “Company”) today announced financial results for the second quarter ended June 30, 2021.

Second Quarter 2021 Highlights

  • Received seven new orders for MRIdian systems totaling $37.9 million, compared to four new orders totaling $24.6 million in the second quarter of 2020.
  • Total backlog increased to $278.4 million as of June 30, 2021, compared to $232.2 million as of June 30, 2020.
  • Total revenue of $15.0 million primarily from two revenue units, compared to $14.2 million primarily from two revenue units in the second quarter of 2020.
  • Cash usage in the second quarter of 2021 was approximately $15 million compared to approximately $11 million in the second quarter of 2020.
  • Cash and cash equivalents were $166.9 million as of June 30, 2021.

“Our second quarter performance is a solid step forward and reflects progress on our commercial, innovation, and clinical pipelines. Our team has executed very well in an environment that continues to be challenging,” said Scott Drake, President and CEO.  “We are well positioned to drive further growth, therapy adoption, and extend our innovation lead.”

Three Months Ended June 30, 2021 Financial Results

Total revenue for the three months ended June 30, 2021 was $15.0 million compared to $14.2 million for the same period last year.

Total gross profit (loss) for the three months ended June 30, 2021 was ($1.7) million, compared to ($1.0) million for the same period last year.

Total operating expenses for the three months ended June 30, 2021 were $24.8 million, compared to $24.5 million for the same period last year.

Net loss for the three months ended June 30, 2021 was $31.0 million, or $0.19 per share, compared to $26.2 million, or $0.18 per share, for the same period last year.

ViewRay had total cash and cash equivalents of $166.9 million at June 30, 2021.

Six Months Ended June 30, 2020 Financial Results:

Total revenue for the six months ended June 30, 2021 was $30.6 million compared to $28.5 million for the same period last year.

Total gross profit (loss) for the six months ended June 30, 2021 was $(1.4) million, compared to $(3.1) million for the same period last year.

Total operating expenses for the six months ended June 30, 2021 were $49.8 million, compared to $52.5 million for the same period last year.

Net loss for the six months ended June 30, 2021 was $57.7 million, or $0.36 per share, compared to $53.7 million, or $0.36 per share, for the same period last year.

Financial Guidance
For the full year 2021, ViewRay anticipates total revenue to be in the range of $63 million to $73 million, and total cash usage to be in the range of $58 million to $68 million.

Conference Call and Webcast
ViewRay will hold a conference call to discuss results on Thursday, August 5, 2021 at 4:30 p.m. ET / 1:30 p.m. PT. The dial-in numbers are (844) 277-1426 for domestic callers and (336) 525-7129 for international callers. The confirmation number is 8473598. A live webcast of the conference call will be available on the investor relations page of ViewRay’s corporate website at http://investors.viewray.com/events-and-presentations/upcoming-events.

After the live webcast, a replay will remain available online on the investor relations page of ViewRay’s website, under “Financial Events and Webinars”, for 14 days following the call. In addition, a telephonic replay of the call will be available for seven days after the call. The replay dial-in numbers are (855) 859-2056 for domestic callers and (404) 537-3406 for international callers. Please use the conference ID number 8473598.

About ViewRay®
ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures, and markets the MRIdian® MR-Guided Radiation Therapy System. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian’s high-definition MR was purpose-built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.             

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Private Securities Litigation Reform Act. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, anticipated future orders, ViewRay’s financial guidance for the full year 2021, anticipated future operating and financial performance, treatment results, therapy adoption, innovation and the performance of the MRIdian systems. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to commercialize MRIdian Linac System, demand for ViewRay’s products, the ability to convert backlog into revenue, the timing of delivery of ViewRay’s products, the timing, length, and severity of the recent COVID-19 (coronavirus) pandemic, including its impacts across our businesses on demand, operations and our global supply chains, the results and other uncertainties associated with clinical trials, the ability to raise the additional funding needed to continue to pursue ViewRay’s business and product development plans, the inherent uncertainties associated with developing new products or technologies, competition in the industry in which ViewRay operates, and overall market conditions. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to ViewRay’s business in general, see ViewRay’s current and future reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and its Quarterly Reports on Form 10-Q, as updated periodically with the Company’s other filings with the SEC. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.

 


VIEWRAY, INC.


Consolidated Statements of Operations and Comprehensive Loss


(Unaudited)



(In thousands, except share and per share data)


For the Three Months Ended
June

 
30,


For the Six Months Ended
June

 
30,


2021


2020


2021


2020

Revenue:

Product

$

10,917

$

10,615

$

22,296

$

22,085

Service

3,994

3,490

8,021

6,151

Distribution rights

119

119

238

238

Total revenue

15,030

14,224

30,555

28,474

Cost of revenue:

Product

12,180

12,714

22,865

25,843

Service

4,522

2,552

9,040

5,780

Total cost of revenue

16,702

15,266

31,905

31,623

Gross profit (loss)

(1,672)

(1,042)

(1,350)

(3,149)

Operating expenses:

Research and development

7,903

6,211

14,413

12,548

Selling and marketing

3,052

3,093

5,900

8,916

General and administrative

13,858

15,227

29,497

31,015

Total operating expenses

24,813

24,531

49,810

52,479

Loss from operations

(26,485)

(25,573)

(51,160)

(55,628)

Interest income

3

87

5

782

Interest expense

(1,060)

(1,071)

(2,118)

(2,109)

Other income (expense), net

(3,434)

405

(4,446)

3,271

Loss before provision for income taxes

$

(30,976)

$

(26,152)

$

(57,719)

$

(53,684)

Provision for income taxes

Net loss and comprehensive loss

$

(30,976)

$

(26,152)

$

(57,719)

$

(53,684)

Amortization of beneficial conversion feature related to Series A
convertible preferred stock

Net loss attributable to common stockholders, basic and diluted

$

(30,976)

$

(26,152)

$

(57,719)

$

(53,684)

Net loss per share, basic and diluted

$

(0.19)

$

(0.18)

$

(0.36)

$

(0.36)

Weighted-average common shares used to compute net loss per

   share attributable to common stockholders, basic and diluted

162,283,348

147,563,278

161,217,083

147,506,244

Gross Orders

$

37,900

$

24,600

$

78,750

$

47,200

Backlog

$

278,434

$

232,273

$

278,434

$

232,273

 




VIEWRAY, INC.


Consolidated Balance Sheets


(Unaudited)



(In thousands, except share and per share data)


June
 
30, 2021


December 31, 2020


ASSETS

Current assets:

Cash and cash equivalents

$

166,925

$

156,720

Accounts receivable

15,416

11,769

Inventory, net of allowance of $2,181 and $2,286, respectively

41,878

46,641

Deposits on purchased inventory

3,679

2,084

Deferred cost of revenue

1,199

1,954

Prepaid expenses and other current assets

5,101

5,257

Total current assets

234,198

224,425

Property and equipment, net

21,754

24,062

Restricted cash

1,460

1,460

Intangible assets, net

47

50

Right-of-use assets

9,018

10,129

Other assets

7,392

1,426

TOTAL ASSETS

$

273,869

$

261,552


LIABILITIES AND STOCKHOLDERS

 EQUITY

Current liabilities:

Accounts payable

$

7,525

$

9,984

Accrued liabilities

18,304

19,281

Customer deposits

14,183

15,463

Operating lease liability, current

1,938

2,089

Deferred revenue, current

11,041

10,094

Total current liabilities

52,991

56,911

Deferred revenue, net of current portion

4,962

2,572

Long-term debt

57,101

56,940

Warrant liabilities

9,212

4,864

Operating lease liability, noncurrent

8,039

9,043

Other long-term liabilities

2,513

956

TOTAL LIABILITIES

134,818

131,286

Commitments and contingencies (Note 6)

Stockholders’ equity:

Preferred stock, par value of $0.01 per share; 10,000,000 shares authorized

  at June 30, 2021 and December 31, 2020; no shares issued and outstanding

  at June 30, 2021 and December 31, 2020

Common stock, par value of $0.01 per share; 300,000,000 shares authorized at

  June 30, 2021 and December 31, 2020; 163,590,744 and 148,615,351 shares

  issued and outstanding at June 30, 2021 and December 31, 2020

1,624

1,476

Additional paid-in capital

822,230

755,874

Accumulated deficit

(684,803)

(627,084)

TOTAL STOCKHOLDERS’ EQUITY

139,051

130,266

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY

$

273,869

$

261,552

 

 

Cision View original content:https://www.prnewswire.com/news-releases/viewray-reports-second-quarter-2021-results-301349758.html

SOURCE ViewRay, Inc.

OpenText Reports Fourth Quarter and Fiscal Year 2021 Financial Results

PR Newswire

Record Annual Total Revenues with Cloud Revenue Growth of 21.6%

Repurchases 2.5 Million Common Shares and Increases Dividend by 10%

WATERLOO, ON, Aug. 5, 2021 /PRNewswire/ —


Fiscal 2021 Fourth Quarter Highlights Y/Y


Total Revenues

(in millions)


Annual Recurring Revenues

(in millions)


Cloud Revenues

(in millions)


Reported


Constant Currency


Reported


Constant Currency


Reported


Constant Currency

$893.5

$859.4

$694.4

$671.8

$360.2

$352.7

+8.1%

+4.0%

+5.6%

+2.2%

+8.3%

+6.0%

Annual Recurring Revenues represent 78% of Total Revenues

 

  • Operating cash flows were $296.2 million and free cash flows were $268.8 million
  • GAAP-based net income of $181.3 million, up 586.9% Y/Y, margin of 20.3%, up 1,710 basis points Y/Y
  • Adjusted EBITDA of $314.8 million, down 0.8%, margin of 35.2%, down 320 basis points Y/Y
  • GAAP-based diluted EPS of $0.66, up 560.0% Y/Y
  • Non-GAAP diluted EPS of $0.80, constant Y/Y
  • During the quarter, the company repurchased and cancelled 2.5 million common shares for $119.1 million under our Share Repurchase Plan
  • Quarterly cash dividend increased by 10%

 


Fiscal 2021 Annual Highlights Y/Y


Total Revenues

(in millions)


Annual Recurring Revenues

(in millions)


Cloud Revenues

(in millions)


Reported


Constant Currency


Reported


Constant Currency


Reported


Constant Currency

$3,386.1

$3,304.8

$2,741.5

$2,686.6

$1,407.4

$1,389.7

+8.9%

+6.3%

+12.7%

+10.4%

+21.6%

+20.0%

Annual Recurring Revenues represent 81% of Total Revenues

 

  • Operating cash flows were $876.1 million and free cash flows were $812.4 million, which include the IRS settlement payment of $299.6 million
  • GAAP-based net income of $310.7 million, up 32.6% Y/Y, margin of 9.2%, up 170 basis points Y/Y
  • Adjusted EBITDA of $1,315.0 million, up 14.5%, margin of 38.8%, up 190 basis points Y/Y
  • GAAP-based diluted EPS of $1.14, up 32.6% Y/Y
  • Non-GAAP diluted EPS of $3.39, up 17.3% Y/Y

Open Text Corporation (NASDAQ: OTEX), (TSX: OTEX), today announced its financial results for the fourth quarter and year ended June 30, 2021.

“Our robust fourth quarter results contributed to a record fiscal year, as we successfully helped our customers navigate the challenges of an evolving market and workforce,” said Mark J. Barrenechea, OpenText CEO & CTO.  “In Fiscal 2021, OpenText delivered a record $3.39 billion in total revenues, up 8.9% year-over-year, supported by record Cloud revenues of $1.4 billion, up 21.6% from a year ago. Annual Recurring Revenues (ARR) reached a record $2.7 billion, up 12.7% year-over-year, representing 81% of total revenues.”

“Information Management’s time has come, and OpenText is perfectly positioned to lead the market as we digitally empower many of the most innovative global organizations, in nearly every vertical and line of business.  OpenText Cloud Editions enables customers to accelerate growth and stay ahead of the competition by maximizing the value of their information through our cloud-based Information Management platform.” 

“I am very pleased with our fourth quarter and Fiscal 2021 results,” said Madhu Ranganathan, OpenText EVP, CFO.  “In Fiscal 2021, we excelled in our operational performance, generating a record $1.3 billion of adjusted EBITDA, up 14.5% year-over-year, and free cash flows of $812.4 million which includes the IRS settlement payment of $299.6 million.  With approximately $1.6 billion of cash as of June 30, 2021, and a net leverage ratio of 1.5x, our balance sheet and liquidity position remain strong.  We are well positioned to drive our organic growth initiatives and to deploy capital that meet OpenText’s growth and returns based metrics.”



Financial Highlights for Q4 and Fiscal 2021 with Year Over Year Comparisons



Summary of Quarterly Results


(In millions, except per share data)


Q4 FY’21


Q4 FY’20


$ Change 


% Change 


Q4 FY’21 in CC*


% Change in CC*


Revenues:

Cloud services and subscriptions

$360.2

$332.6

$27.5

8.3

%

$352.7

6.0

%

Customer support

334.3

324.9

9.3

2.9

%

319.1

(1.8)

%


Total annual recurring revenues**


$694.4


$657.5


$36.9


5.6


%


$671.8


2.2


%

License

132.5

105.8

26.7

25.3

%

124.6

17.8

%

Professional service and other

66.6

63.3

3.3

5.2

%

63.0

(0.4)

%


Total revenues


$893.5


$826.6


$66.9


8.1


%


$859.4


4.0


%

GAAP-based operating income

$171.7

$91.2

$80.5

88.2

%

N/A

N/A

Non-GAAP-based operating income (1)

$293.9

$293.8

$0.1

%

$285.7

(2.7)

%

GAAP-based net income attributable to OpenText

$181.3

$26.4

$154.9

586.9

%

N/A

N/A

GAAP-based EPS, diluted

$0.66

$0.10

$0.56

560.0

%

N/A

N/A

Non-GAAP-based EPS, diluted (1)(2)

$0.80

$0.80

$—

%

$0.78

(2.5)

%

Adjusted EBITDA (1)

$314.8

$317.4

($2.6)

(0.8)

%

$306.3

(3.5)

%

Operating cash flows

$296.2

$280.3

$15.9

5.7

%

N/A

N/A

Free cash flows (1)

$268.8

$262.5

$6.2

2.4

%

N/A

N/A

 



Summary of Annual Results


(In millions, except per share data)


FY’21


FY’20


$ Change 


% Change 


FY’21 in CC*


% Change in CC*


Revenues:

Cloud services and subscriptions

$1,407.4

$1,157.7

$249.8

21.6

%

$1,389.7

20.0

%

Customer support

1,334.1

1,275.6

58.5

4.6

%

1,297.0

1.7

%


Total annual recurring revenues**


$2,741.5


$2,433.3


$308.2


12.7


%


$2,686.6


10.4


%

License

384.7

402.9

(18.1)

(4.5)

%

368.1

(8.6)

%

Professional service and other

259.9

273.6

(13.7)

(5.0)

%

250.0

(8.6)

%


Total revenues


$3,386.1


$3,109.7


$276.4


8.9


%


$3,304.8


6.3


%

GAAP-based operating income

$740.9

$503.5

$237.4

47.1

%

N/A

N/A

Non-GAAP-based operating income (1)

$1,230.0

$1,058.8

$171.2

16.2

%

$1,193.9

12.8

%

GAAP-based net income attributable to OpenText

$310.7

$234.2

$76.4

32.6

%

N/A

N/A

GAAP-based EPS, diluted

$1.14

$0.86

$0.28

32.6

%

N/A

N/A

Non-GAAP-based EPS, diluted (1)(2)

$3.39

$2.89

$0.50

17.3

%

$3.28

13.5

%

Adjusted EBITDA (1)

$1,315.0

$1,148.1

$167.0

14.5

%

$1,278.2

11.3

%

Operating cash flows

$876.1

$954.5

($78.4)

(8.2)

%

N/A

N/A

Free cash flows (1)

$812.4

$881.8

($69.4)

(7.9)

%

N/A

N/A


(1)

Please see note 2 “Use of Non-GAAP Financial Measures” below.


(2)

Please also see note 14 to the Company’s Fiscal 2018 Consolidated Financial Statements on Form 10-K. Reflective of the amount of net tax benefit arising from the internal reorganization assumed to be allocable to the current period based on the forecasted utilization period.

Note:

Individual line items in tables may be adjusted by non-material amounts to enable totals to align to published financial statements.

*CC:

Constant currency for this purpose is defined as the current period reported revenues/expenses/earnings represented at the prior comparative period’s foreign exchange rate.

**

Annual recurring revenue is defined as the sum of Cloud services and subscriptions revenue and Customer support revenue.

 


Dividend and Share Repurchases
 

As part of our quarterly, non-cumulative cash dividend program, the Board declared on August 4, 2021, a cash dividend increase of 10% to $0.2209 per common share. The record date for this dividend is September 3, 2021 and the payment date is September 24, 2021. OpenText believes strongly in returning value to its shareholders and intends to maintain its dividend program. Any future declarations of dividends and the establishment of future record and payment dates are all subject to the final determination and discretion of the Board of Directors.

“Since Fiscal 2013, OpenText has delivered approximately $1.3 billion to shareholders through our dividend and share repurchase programs. In Fiscal 2021 we repurchased and cancelled 2.5 million common shares through our share repurchase plan, and in the next fiscal year, we expect to increase shareholder returns by allocating approximately 33% of free cash flows towards both our dividend and share repurchase programs,” said Mark J. Barrenechea.


Quarterly Business Highlights

  • Key customer wins in the quarter included VMware, Wells Fargo, EDF, Cerner, Raytheon, Revlon, Froneri, DHL, Transport for London, Big Cart Holdings, California Department of State Hospitals, Enercon, Multibank Panama, Netherlands Police, Rapid Radiology and Services Australia
  • Cloud Editions 21.3 strengthens Information Management in the cloud at scale
  • OpenText partners with Google Cloud to extend availability of solution extensions for SAP® applications to the Asia Pacific Japan region
  • Industry-leading solutions from OpenText Complement RISE with SAP
  • OpenText launches Managed Detection and Response (MDR) Service
  • OpenText named a leader in Content Platforms by Forrester
  • OpenText recognized as an overall leader for fourth consecutive year in the 2021 Customer Communications Management Aspire Leaderboard
  • OpenText World Asia Pacific showcases OpenText Cloud Editions
  • Published our second Corporate Citizenship Report confirming our commitment to ESG

 



Summary of Quarterly Results


Q4 FY’21


Q3 FY’21


Q4 FY’20


% Change 


(Q4 FY’21 vs Q3 FY’21)


% Change


(Q4 FY’21 vs Q4 FY’20)

Revenue (millions)

$893.5

$832.9

$826.6

7.3

%

8.1

%

GAAP-based gross margin

69.6

%

68.6

%

68.5

%

100

bps

110

bps

Non-GAAP-based gross margin (1)

75.8

%

75.2

%

75.8

%

60

bps

bps

GAAP-based EPS, diluted

$0.66

$0.33

$0.10

100.0

%

560.0

%

Non-GAAP-based EPS, diluted (1)(2)

$0.80

$0.75

$0.80

6.7

%

%

 



Summary of Annual Results


FY’21


FY’20


% Change

Revenue (millions)

$3,386.1

$3,109.7

8.9

%

GAAP-based gross margin

69.4

%

67.7

%

170

bps

Non-GAAP-based gross margin (1)

76.1

%

74.5

%

160

bps

GAAP-based EPS, diluted

$1.14

$0.86

32.6

%

Non-GAAP-based EPS, diluted (1)(2)

$3.39

$2.89

17.3

%


(1) 

Please see note 2 “Use of Non-GAAP Financial Measures” below.


(2)

Please also see note 14 to the Company’s Fiscal 2018 Consolidated Financial Statements on Form 10-K. Reflective of the amount of net tax benefit arising from the internal reorganization assumed to be allocable to the current period based on the forecasted utilization period.


Conference Call Information

The public is invited to listen to the earnings conference call today at 5:00 p.m. ET (2:00 p.m. PT) by dialing 1-800-319-4610 (toll-free) or +1-604-638-5340 (international). Please dial-in 10 minutes ahead of time to ensure proper connection. Alternatively, a live webcast of the earnings conference call will be available on the Investor Relations section of the Company’s website at http://investors.opentext.com/investor-events-and-presentations.  

A replay of the call will be available beginning August 5, 2021 at 7:00 p.m. ET through 11:59 p.m. on August 19, 2021 and can be accessed by dialing 1-855-669-9658 (toll-free) or +1-604-674-8052 (international) and using passcode 7298 followed by the number sign.

Please see below note (2) for a reconciliation of U.S. GAAP-based financial measures used in this press release, to Non-GAAP-based financial measures. Additionally, “off-cloud” is a term we use to describe license transactions.


About OpenText

OpenText, The Information Company™, enables organizations to gain insight through market leading information management solutions, powered by OpenText Cloud Editions. For more information about OpenText (NASDAQ: OTEX, TSX: OTEX) visit opentext.com.


Cautionary Statement Regarding Forward-Looking Statements

Certain statements in this press release, including statements about the focus of Open Text Corporation (“OpenText” or “the Company”) in our fiscal year ending June 30, 2022 (Fiscal 2022) on growth, future cloud growth and market share gains, future organic growth initiatives and deployment of capital, declaration of quarterly dividends, potential share repurchases pursuant to its Repurchase Plan, future tax rates, new platform and product offerings, scaling OpenText to new levels in Fiscal 2022 and beyond, and other matters, may contain words such as “anticipates”, “expects”, “intends”, “plans”, “believes”, “seeks”, “estimates”, “may”, “could”, “would”, “might”, “will” and variations of these words or similar expressions are considered forward-looking statements or information under applicable securities laws. In addition, any information or statements that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking, and based on our current expectations, forecasts and projections about the operating environment, economies and markets in which we operate. Forward-looking statements reflect our current estimates, beliefs and assumptions, which are based on management’s perception of historic trends, current conditions and expected future developments, as well as other factors it believes are appropriate in the circumstances, such as certain assumptions about the economy, as well as market, financial and operational assumptions. Management’s estimates, beliefs and assumptions are inherently subject to significant business, economic, competitive and other uncertainties and contingencies regarding future events and, as such, are subject to change. We can give no assurance that such estimates, beliefs and assumptions will prove to be correct. Such forward-looking statements involve known and unknown risks, uncertainties and other factors and assumptions that may cause the actual results, performance or achievements to differ materially which include, but are not limited to, actual and potential risks and uncertainties relating to the ultimate spread of COVID-19, the severity of the disease and the duration of the COVID-19 pandemic. For additional information with respect to risks and other factors which could occur, see the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other securities filings with the Securities and Exchange Commission (SEC) and other securities regulators. Readers are cautioned not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

OTEX-F

For more information, please contact:


Harry E. Blount

Senior Vice President, Global Head of Investor Relations
Open Text Corporation
415-963-0825
[email protected]

Copyright ©2021 Open Text. OpenText is a trademark or registered trademark of Open Text. The list of trademarks is not exhaustive of other trademarks. Registered trademarks, product names, company names, brands and service names mentioned herein are property of Open Text. All rights reserved. For more information, visit: http://www.opentext.com/who-we-are/copyright-information.

 


OPEN TEXT CORPORATION

CONSOLIDATED BALANCE SHEETS

(In thousands of U.S. dollars, except share data)


June 30, 2021


June 30, 2020


ASSETS

Cash and cash equivalents

$

1,607,306

$

1,692,850

Accounts receivable trade, net of allowance for credit losses of $22,151 as of June 30, 2021 and $20,906 as of June 30, 2020

438,547

466,357

Contract assets

25,344

29,570

Income taxes recoverable

32,312

61,186

Prepaid expenses and other current assets

98,551

136,436

Total current assets

2,202,060

2,386,399

Property and equipment

233,595

244,555

Operating lease right of use assets

234,532

207,869

Long-term contract assets

19,222

15,427

Goodwill

4,691,673

4,672,356

Acquired intangible assets

1,187,260

1,612,564

Deferred tax assets

796,738

911,565

Other assets

208,894

154,467

Long-term income taxes recoverable

35,362

29,620


Total assets

$

9,609,336

$

10,234,822


LIABILITIES AND SHAREHOLDERS’ EQUITY

Current liabilities:

Accounts payable and accrued liabilities

$

423,592

$

373,314

Current portion of long-term debt

10,000

610,000

Operating lease liabilities

58,315

64,071

Deferred revenues

852,629

812,218

Income taxes payable

17,368

44,630

Total current liabilities

1,361,904

1,904,233

Long-term liabilities:

Accrued liabilities

28,830

34,955

Pension liability

74,511

73,129

Long-term debt

3,578,859

3,584,311

Long-term operating lease liabilities

224,453

217,165

Long-term deferred revenues

98,989

94,382

Long-term income taxes payable

34,113

171,200

Deferred tax liabilities

108,224

148,738

Total long-term liabilities

4,147,979

4,323,880

Shareholders’ equity:

Share capital and additional paid-in capital

271,540,755 and 271,863,354 Common Shares issued and outstanding at June 30, 2021 and June 30, 2020, respectively; authorized Common Shares: unlimited

1,947,764

1,851,777

Accumulated other comprehensive income

66,238

17,825

Retained earnings

2,153,326

2,159,396

Treasury stock, at cost (1,567,664 and 622,297 shares at June 30, 2021 and June 30, 2020, respectively)

(69,386)

(23,608)

Total OpenText shareholders’ equity

4,097,942

4,005,390

Non-controlling interests

1,511

1,319

Total shareholders’ equity

4,099,453

4,006,709


Total liabilities and shareholders’ equity

$

9,609,336

$

10,234,822

 


OPEN TEXT CORPORATION

CONSOLIDATED STATEMENTS OF INCOME

(In thousands of U.S. dollars, except share and per share data)

(unaudited)


Three Months Ended June 30,


2021


2020

Revenues:

Cloud services and subscriptions

$

360,160

$

332,618

Customer support

334,256

324,915

License

132,541

105,803

Professional service and other

66,570

63,276

Total revenues

893,527

826,612

Cost of revenues:

Cloud services and subscriptions

127,583

116,569

Customer support

32,938

32,568

License

4,315

3,404

Professional service and other

53,662

48,435

Amortization of acquired technology-based intangible assets

53,215

59,719

Total cost of revenues

271,713

260,695

Gross profit

621,814

565,917

Operating expenses:

Research and development

117,235

100,766

Sales and marketing

183,237

152,882

General and administrative

73,019

62,574

Depreciation

21,021

23,649

Amortization of acquired customer-based intangible assets

52,469

58,998

Special charges (recoveries)

3,152

75,849

Total operating expenses

450,133

474,718

Income from operations

171,681

91,199

Other income (expense), net

45,017

7,790

Interest and other related expense, net

(37,550)

(40,529)

Income before income taxes

179,148

58,460

Provision for (recovery of) income taxes

(2,215)

32,037

Net income for the period

$

181,363

$

26,423

Net (income) loss attributable to non-controlling interests

(80)

(31)

Net income attributable to OpenText

$

181,283

$

26,392

Earnings per share—basic attributable to OpenText

$

0.66

$

0.10

Earnings per share—diluted attributable to OpenText

$

0.66

$

0.10

Weighted average number of Common Shares outstanding—basic (in ‘000’s)

272,892

271,717

Weighted average number of Common Shares outstanding—diluted (in ‘000’s)

273,981

272,367

 


OPEN TEXT CORPORATION

CONSOLIDATED STATEMENTS OF INCOME

(In thousands of U.S. dollars, except share and per share data)


Year Ended June 30,


2021


2020


2019

Revenues:

Cloud services and subscriptions

$

1,407,445

$

1,157,686

$

907,812

Customer support

1,334,062

1,275,586

1,247,915

License

384,711

402,851

428,092

Professional service and other

259,897

273,613

284,936

Total revenues

3,386,115

3,109,736

2,868,755

Cost of revenues:

Cloud services and subscriptions

481,818

449,940

383,993

Customer support

122,753

123,894

124,343

License

13,916

11,321

14,347

Professional service and other

197,183

212,903

224,635

Amortization of acquired technology-based intangible assets

218,796

205,717

183,385

Total cost of revenues

1,034,466

1,003,775

930,703

Gross profit

2,351,649

2,105,961

1,938,052

Operating expenses:

Research and development

421,447

370,411

321,836

Sales and marketing

622,221

585,044

518,035

General and administrative

263,521

237,532

207,909

Depreciation

85,265

89,458

97,716

Amortization of acquired customer-based intangible assets

216,544

219,559

189,827

Special charges (recoveries)

1,748

100,428

35,719

Total operating expenses

1,610,746

1,602,432

1,371,042

Income from operations

740,903

503,529

567,010

Other income (expense), net

61,434

(11,946)

10,156

Interest and other related expense, net

(151,567)

(146,378)

(136,592)

Income before income taxes

650,770

345,205

440,574

Provision for (recovery of) income taxes

339,906

110,837

154,937

Net income

$

310,864

$

234,368

$

285,637

Net (income) loss attributable to non-controlling interests

(192)

(143)

(136)

Net income attributable to OpenText

$

310,672

$

234,225

$

285,501

Earnings per share—basic attributable to OpenText

$

1.14

$

0.86

$

1.06

Earnings per share—diluted attributable to OpenText

$

1.14

$

0.86

$

1.06

Weighted average number of Common Shares outstanding—basic

(in ‘000’s)

272,533

270,847

268,784

Weighted average number of Common Shares outstanding—diluted

(in ‘000’s)

273,479

271,817

269,908

 


OPEN TEXT CORPORATION

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(In thousands of U.S. dollars)


Year Ended June 30,


2021


2020


2019

Net income

$

310,864

$

234,368

$

285,637

Other comprehensive income (loss)—net of tax:

Net foreign currency translation adjustments

42,440

(7,784)

(3,882)

Unrealized gain (loss) on cash flow hedges:

Unrealized gain (loss) – net of tax expense (recovery) effect of $1,532, ($599) and $6 for the year ended June 30, 2021, 2020 and 2019, respectively

4,246

(1,662)

16

(Gain) loss reclassified into net income – net of tax (expense) recovery effect of ($1,182), $355 and $539 for the year ended June 30, 2021, 2020 and 2019, respectively

(3,280)

985

1,494

Actuarial gain (loss) relating to defined benefit pension plans:

Actuarial gain (loss) – net of tax expense (recovery) effect of $990, $1,219 and ($2,004) for the year ended June 30, 2021, 2020 and 2019, respectively

3,987

1,245

(7,421)

Amortization of actuarial (gain) loss into net income – net of tax (expense) recovery effect of $379, $520 and $292 for the year ended June 30, 2021, 2020 and 2019, respectively

1,020

917

272

Total other comprehensive income (loss) net

48,413

(6,299)

(9,521)

Total comprehensive income

359,277

228,069

276,116

Comprehensive (income) loss attributable to non-controlling interests

(192)

(143)

(136)

Total comprehensive income attributable to OpenText

$

359,085

$

227,926

$

275,980

 




OPEN TEXT CORPORATION

CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY

(In thousands of U.S. dollars and shares)


Common Shares and
Additional Paid in Capital


Treasury Stock


Retained


Earnings


Accumulated  Other


Comprehensive


Income


Non-Controlling Interests


Total


Shares


Amount


Shares


Amount


Balance as of June 30, 2018


267,651


$


1,707,073


(691)


$


(18,732)


$


1,994,235


$


33,645


$


1,037


$


3,717,258

Issuance of Common Shares

Under employee stock option plans

1,472

35,626

35,626

Under employee stock purchase plans

711

21,835

21,835

Share-based compensation

26,770

26,770

Purchase of treasury stock

(726)

(26,499)

(26,499)

Issuance of treasury stock

(16,465)

614

16,465

Dividends declared

($0.6300 per Common Share)

(168,859)

(168,859)

Cumulative effect of ASU 2016-16

(26,780)

(26,780)

Cumulative effect of Topic 606

29,786

29,786

Other comprehensive income (loss) – net

(9,521)

(9,521)

Non-controlling interest

(625)

42

(583)

Net income

285,501

136

285,637


Balance as of June 30, 2019


269,834


$


1,774,214


(803)


$


(28,766)


$


2,113,883


$


24,124


$


1,215


$


3,884,670

Issuance of Common Shares

Under employee stock option plans

1,530

41,282

41,282

Under employee stock purchase plans

499

17,757

17,757

Share-based compensation

29,532

29,532

Purchase of treasury stock

(300)

(12,424)

(12,424)

Issuance of treasury stock

(11,008)

481

17,582

6,574

Dividends declared

($0.6984 per Common Share)

(188,712)

(188,712)

Other comprehensive income (loss) – net

(6,299)

(6,299)

Non-controlling interest

(39)

(39)

Net income

234,225

143

234,368


Balance as of June 30, 2020


271,863


$


1,851,777


(622)


$


(23,608)


$


2,159,396


$


17,825


$


1,319


$


4,006,709

Adoption of ASU 2016-13 – cumulative effect, net

(2,450)

(2,450)

Issuance of Common Shares

Under employee stock option plans

1,605

49,565

49,565

Under employee stock purchase plans

573

22,307

193

6,690

28,997

Share-based compensation

51,969

51,969

Purchase of treasury stock

(1,455)

(64,847)

(64,847)

Issuance of treasury stock

(12,379)

316

12,379

Repurchase of Common Shares

(2,500)

(15,475)

(103,630)

(119,105)

Dividends declared

($0.7770 per Common Share)

(210,662)

(210,662)

Other comprehensive income (loss) – net

48,413

48,413

Net income

310,672

192

310,864


Balance as of June 30, 2021


271,541


$


1,947,764


(1,568)


$


(69,386)


$


2,153,326


$


66,238


$


1,511


$


4,099,453

 


OPEN TEXT CORPORATION

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands of U.S. dollars)

(unaudited)


Three Months Ended June 30,


2021


2020

Cash flows from operating activities:

Net income for the period

$

181,363

$

26,423

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation and amortization of intangible assets

126,705

142,366

Share-based compensation expense

13,350

8,002

Pension expense

1,946

1,479

Amortization of debt issuance costs

1,153

1,130

Accelerated amortization of right of use assets

36,864

Loss on sale and write down of property and equipment

792

9,714

Deferred taxes

(7,805)

14,677

Share in net (income) loss of equity investees

(42,877)

(2,225)

Changes in operating assets and liabilities:

Accounts receivable

(26,118)

(1,689)

Contract assets

(10,298)

(13,636)

Prepaid expenses and other current assets

40,261

458

Income taxes

(23,169)

(478)

Accounts payable and accrued liabilities

53,415

72,876

Deferred revenue

(23,305)

(12,974)

Other assets

11,149

(6,309)

Operating lease assets and liabilities, net

(373)

3,572

Net cash provided by operating activities

296,189

280,250

Cash flows from investing activities:

Additions of property and equipment

(27,408)

(17,704)

Purchase of Dynamic Solutions Group Inc.

(600)

Other investing activities

(2,550)

(2,783)

Net cash used in investing activities

(30,558)

(20,487)

Cash flows from financing activities:

Proceeds from issuance of Common Shares from exercise of stock options and ESPP

34,287

13,493

Repayment of long-term debt and Revolver

(2,500)

(2,500)

Debt issuance costs

(3,636)

Repurchase of Common Shares

(119,105)

Payments of dividends to shareholders

(54,374)

(47,335)

Net cash provided by (used in) financing activities

(141,692)

(39,978)

Foreign exchange gain (loss) on cash held in foreign currencies

7,181

19,882

Increase (decrease) in cash, cash equivalents and restricted cash during the period

131,120

239,667

Cash, cash equivalents and restricted cash at beginning of the period

1,478,680

1,457,596

Cash, cash equivalents and restricted cash at end of the period

$

1,609,800

$

1,697,263


Reconciliation of cash, cash equivalents and restricted cash:


June 30, 2021


June 30, 2020

Cash and cash equivalents

$

1,607,306

$

1,692,850

Restricted cash (1)

2,494

4,413

Total cash, cash equivalents and restricted cash

$

1,609,800

$

1,697,263


(1) Restricted cash is classified under the Prepaid expenses and other current assets and Other assets line items on the Consolidated Balance Sheets.

 


OPEN TEXT CORPORATION

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands of U.S. dollars)


Year Ended June 30,


2021


2020


2019

Cash flows from operating activities:

Net income

$

310,864

$

234,368

$

285,637

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation and amortization of intangible assets

520,605

514,734

470,928

Share-based compensation expense

51,969

29,532

26,770

Pension expense

6,616

5,802

4,624

Amortization of debt issuance costs

4,548

4,633

4,330

Accelerated amortization of right of use assets

36,864

Loss on extinguishment of debt

17,854

Loss on sale and write down of property and equipment

2,771

9,714

9,438

Deferred taxes

73,039

51,388

47,425

Share in net (income) loss of equity investees

(62,897)

(8,700)

(13,668)

Changes in operating assets and liabilities:

Accounts receivable

60,954

84,499

75,508

Contract assets

(39,333)

(40,301)

(37,623)

Prepaid expenses and other current assets

37,733

(6,897)

(819)

Income taxes

(140,763)

(35,086)

27,291

Accounts payable and accrued liabilities

26,088

30,613

(21,732)

Deferred revenue

39,295

25,306

(1,827)

Other assets

11,914

1,127

(4)

Operating lease assets and liabilities, net

(27,283)

(914)

Net cash provided by operating activities

876,120

954,536

876,278

Cash flows from investing activities:

Additions of property and equipment

(63,675)

(72,709)

(63,837)

Purchase of XMedius

444

(73,335)

Purchase of Carbonite, Inc., net of cash and restricted cash acquired

(1,305,097)

Purchase of Dynamic Solutions Group Inc.

(971)

(4,149)

Purchase of Catalyst Repository Systems Inc.

(70,800)

Purchase of Liaison Technologies, Inc.

(310,644)

Purchase of Guidance Software, Inc., net of cash acquired

(2,279)

Other investing activities

(4,568)

(14,127)

(16,966)

Net cash used in investing activities

(68,770)

(1,469,417)

(464,526)

Cash flows from financing activities:

Proceeds from issuance of Common Shares from exercise of stock options and ESPP

80,067

66,600

57,889

Proceeds from long-term debt and Revolver

3,150,000

Repayment of long-term debt and Revolver

(610,000)

(1,713,631)

(10,000)

Debt extinguishment costs

(11,248)

Debt issuance costs

(21,806)

(322)

Repurchase of Common Shares

(119,105)

Purchase of treasury stock

(64,847)

(12,424)

(26,499)

Purchase of non-controlling interest

(583)

Payments of dividends to shareholders

(210,662)

(188,712)

(168,859)

Net cash provided by (used in) financing activities

(924,547)

1,268,779

(148,374)

Foreign exchange gain (loss) on cash held in foreign currencies

29,734

(178)

(3,826)

Increase (decrease) in cash, cash equivalents and restricted cash during the period

(87,463)

753,720

259,552

Cash, cash equivalents and restricted cash at beginning of the period

1,697,263

943,543

683,991

Cash, cash equivalents and restricted cash at end of the period

$

1,609,800

$

1,697,263

$

943,543

 


OPEN TEXT CORPORATION

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands of U.S. dollars)


Reconciliation of cash, cash equivalents and restricted cash:


June 30, 2021


June 30, 2020


June 30, 2019

Cash and cash equivalents

$

1,607,306

$

1,692,850

$

941,009

Restricted cash (1)

2,494

4,413

2,534

Total cash, cash equivalents and restricted cash

$

1,609,800

$

1,697,263

$

943,543


(1) Restricted cash is classified under the Prepaid expenses and other current assets and Other assets line items on the Consolidated Balance Sheets.

 





Notes

(1)  All dollar amounts in this press release are in U.S. Dollars unless otherwise indicated.

(2)  Use of Non-GAAP Financial Measures: In addition to reporting financial results in accordance with U.S. GAAP, the Company provides certain financial measures that are not in accordance with U.S. GAAP (Non-GAAP). These Non-GAAP financial measures have certain limitations in that they do not have a standardized meaning and thus the Company’s definition may be different from similar Non-GAAP financial measures used by other companies and/or analysts and may differ from period to period. Thus it may be more difficult to compare the Company’s financial performance to that of other companies. However, the Company’s management compensates for these limitations by providing the relevant disclosure of the items excluded in the calculation of these Non-GAAP financial measures both in its reconciliation to the U.S. GAAP financial measures and its consolidated financial statements, all of which should be considered when evaluating the Company’s results.

The Company uses these Non-GAAP financial measures to supplement the information provided in its consolidated financial statements, which are presented in accordance with U.S. GAAP. The presentation of Non-GAAP financial measures is not meant to be a substitute for financial measures presented in accordance with U.S. GAAP, but rather should be evaluated in conjunction with and as a supplement to such U.S. GAAP measures. OpenText strongly encourages investors to review its financial information in its entirety and not to rely on a single financial measure. The Company therefore believes that despite these limitations, it is appropriate to supplement the disclosure of the U.S. GAAP measures with certain Non-GAAP measures defined below.

Non-GAAP-based net income and Non-GAAP-based EPS, attributable to OpenText, are consistently calculated as GAAP-based net income or earnings per share, attributable to OpenText, on a diluted basis, excluding the effects of the amortization of acquired intangible assets, other income (expense), share-based compensation, and special charges (recoveries), all net of tax and any tax benefits/expense items unrelated to current period income, as further described in the tables below. Non-GAAP-based gross profit is the arithmetical sum of GAAP-based gross profit and the amortization of acquired technology-based intangible assets and share-based compensation within cost of sales. Non-GAAP-based gross margin is calculated as Non-GAAP-based gross profit expressed as a percentage of total revenue. Non-GAAP-based income from operations is calculated as GAAP-based income from operations, excluding the amortization of acquired intangible assets, special charges (recoveries), and share-based compensation expense.

Adjusted earnings before interest, taxes, depreciation and amortization (Adjusted EBITDA) is consistently calculated as GAAP-based net income, attributable to OpenText, excluding interest income (expense), provision for income taxes, depreciation and amortization of acquired intangible assets, other income (expense), share-based compensation and special charges (recoveries). Adjusted EBITDA margin is calculated as adjusted EBITDA expressed as a percentage of total revenue.

The Company’s management believes that the presentation of the above defined Non-GAAP financial measures provides useful information to investors because they portray the financial results of the Company before the impact of certain non-operational charges. The use of the term “non-operational charge” is defined for this purpose as an expense that does not impact the ongoing operating decisions taken by the Company’s management. These items are excluded based upon the way the Company’s management evaluates the performance of the Company’s business for use in the Company’s internal reports and are not excluded in the sense that they may be used under U.S. GAAP.

The Company does not acquire businesses on a predictable cycle, and therefore believes that the presentation of Non-GAAP measures, which in certain cases adjust for the impact of amortization of intangible assets and the related tax effects that are primarily related to acquisitions, will provide readers of financial statements with a more consistent basis for comparison across accounting periods and be more useful in helping readers understand the Company’s operating results and underlying operational trends. Additionally, the Company has engaged in various restructuring activities over the past several years, primarily due to acquisitions and most recently in response to the COVID-19 pandemic, that have resulted in costs associated with reductions in headcount, consolidation of leased facilities and related costs, all which are recorded under the Company’s “Special charges (recoveries)” caption on the Consolidated Statements of Income. Each restructuring activity is a discrete event based on a unique set of business objectives or circumstances, and each differs in terms of its operational implementation, business impact and scope, and the size of each restructuring plan can vary significantly from period to period. Therefore, the Company believes that the exclusion of these special charges (recoveries) will also better aid readers of financial statements in the understanding and comparability of the Company’s operating results and underlying operational trends.

In summary, the Company believes the provision of supplemental Non-GAAP measures allow investors to evaluate the operational and financial performance of the Company’s core business using the same evaluation measures that management uses, and is therefore a useful indication of OpenText’s performance or expected performance of future operations and facilitates period-to-period comparison of operating performance (although prior performance is not necessarily indicative of future performance). As a result, the Company considers it appropriate and reasonable to provide, in addition to U.S. GAAP measures, supplementary Non-GAAP financial measures that exclude certain items from the presentation of its financial results.

The following charts provide unaudited reconciliations of U.S. GAAP-based financial measures to Non-GAAP-based financial measures for the following periods presented.


 



Reconciliation of selected GAAP-based measures to Non-GAAP-based measures



for the three months ended June 30, 2021



(In thousands, except for per share data)


Three Months Ended June 30, 2021


GAAP-based Measures 


GAAP-based Measures


% of Total Revenue


Adjustments 


Note


Non-GAAP-based Measures 


Non-GAAP-based  Measures


% of Total Revenue


Cost of revenues

Cloud services and subscriptions

$

127,583

$

(935)

(1)

$

126,648

Customer support

32,938

(505)

(1)

32,433

Professional service and other

53,662

(698)

(1)

52,964

Amortization of acquired technology-based intangible assets

53,215

(53,215)

(2)


GAAP-based gross profit and gross margin (%) /


Non-GAAP-based gross profit and gross margin (%)

621,814

69.6%

55,353

(3)

677,167

75.8%


Operating expenses

Research and development

117,235

(2,664)

(1)

114,571

Sales and marketing

183,237

(4,718)

(1)

178,519

General and administrative

73,019

(3,830)

(1)

69,189

Amortization of acquired customer-based intangible assets

52,469

(52,469)

(2)

Special charges (recoveries)

3,152

(3,152)

(4)


GAAP-based income from operations / Non-GAAP-based income from operations

171,681

122,186

(5)

293,867

Other income (expense), net

45,017

(45,017)

(6)

Provision for (recovery of) income taxes

(2,215)

38,099

(7)

35,884


GAAP-based net income / Non-GAAP-based net income, attributable to OpenText

181,283

39,070

(8)

220,353


GAAP-based earnings per share / Non-GAAP-based earnings per share-diluted, attributable to OpenText

$

0.66

$

0.14

(8)

$

0.80

(1)

Adjustment relates to the exclusion of share-based compensation expense from our Non-GAAP-based operating expenses as this expense is excluded from our internal analysis of operating results.

(2)

Adjustment relates to the exclusion of amortization expense from our Non-GAAP-based operating expenses as the timing and frequency of amortization expense is dependent on our acquisitions and is hence excluded from our internal analysis of operating results.

(3)

GAAP-based and Non-GAAP-based gross profit stated in dollars and gross margin stated as a percentage of total revenue.

(4)

Adjustment relates to the exclusion of special charges (recoveries) from our Non-GAAP-based operating expenses as special charges (recoveries) are generally incurred in the periods relevant to an acquisition and include certain charges or recoveries that are not indicative or related to continuing operations, and are therefore excluded from our internal analysis of operating results.

(5)

  GAAP-based and Non-GAAP-based income from operations stated in dollars.

(6)

Adjustment relates to the exclusion of other income (expense) from our Non-GAAP-based operating expenses as other income (expense) generally relates to the transactional impact of foreign exchange and is generally not indicative or related to continuing operations and is therefore excluded from our internal analysis of operating results. Other income (expense) also includes our share of income (losses) from our holdings in investments as a limited partner. We do not actively trade equity securities in these privately held companies nor do we plan our ongoing operations based around any anticipated fundings or distributions from these investments. We exclude gains and losses on these investments as we do not believe they are reflective of our ongoing business and operating results.

(7)

Adjustment relates to differences between the GAAP-based tax recovery rate of approximately 1% and a Non-GAAP-based tax rate of approximately 14%; these rate differences are due to the income tax effects of items that are excluded for the purpose of calculating Non-GAAP-based adjusted net income. Such excluded items include amortization, share-based compensation, special charges (recoveries) and other income (expense), net. Also excluded are tax benefits/expense items unrelated to current period income such as changes in reserves for tax uncertainties and valuation allowance reserves, and “book to return” adjustments for tax return filings and tax assessments. Included is the amount of net tax benefits arising from the internal reorganization that occurred in Fiscal 2017 assumed to be allocable to the current period based on the forecasted utilization period. In arriving at our Non-GAAP-based tax rate of approximately 14%, we analyzed the individual adjusted expenses and took into consideration the impact of statutory tax rates from local jurisdictions incurring the expense.

(8)

Reconciliation of GAAP-based net income to Non-GAAP-based net income:

 


Three Months Ended June 30, 2021


Per share diluted

GAAP-based net income, attributable to OpenText

$

181,283

$

0.66

Add:

Amortization

105,684

0.39

Share-based compensation

13,350

0.05

Special charges (recoveries)

3,152

0.01

Other (income) expense, net

(45,017)

(0.16)

GAAP-based provision for (recovery of) income taxes

(2,215)

(0.02)

Non-GAAP-based provision for income taxes

(35,884)

(0.13)

Non-GAAP-based net income, attributable to OpenText

$

220,353

$

0.80

 


Reconciliation of Adjusted EBITDA


Three Months Ended June 30, 2021

GAAP-based net income, attributable to OpenText

$

181,283

Add:

Provision for (recovery of) income taxes

(2,215)

Interest and other related expense, net

37,550

Amortization of acquired technology-based intangible assets

53,215

Amortization of acquired customer-based intangible assets

52,469

Depreciation

21,021

Share-based compensation

13,350

Special charges (recoveries)

3,152

Other (income) expense, net

(45,017)

Adjusted EBITDA

$

314,808

GAAP-based net income margin

20.3

%

Adjusted EBITDA margin

35.2

%

 


Reconciliation of Free cash flows


Three Months Ended June 30, 2021

GAAP-based cash flows provided by operating activities

$

296,189

Add:

Capital expenditures (1)

(27,408)

Free cash flows

$

268,781


(1) Defined as “Additions of property and equipment” in the Consolidated Statements of Cash Flows.

 



Reconciliation of selected GAAP-based measures to Non-GAAP-based measures



for the year ended June 30, 2021



(In thousands, except for per share data)


Year Ended June 30, 2021


GAAP-based


Measures 


GAAP-based Measures


% of Total Revenue


Adjustments 


Note


Non-GAAP-based


Measures 


Non-GAAP-based  Measures


% of Total Revenue


Cost of revenues

Cloud services and subscriptions

$

481,818

$

(3,419)

(1)

$

478,399

Customer support

122,753

(1,910)

(1)

120,843

Professional service and other

197,183

(2,565)

(1)

194,618

Amortization of acquired technology-based intangible assets

218,796

(218,796)

(2)


GAAP-based gross profit and gross margin (%) /


Non-GAAP-based gross profit and gross margin (%)

2,351,649

69.4%

226,690

(3)

2,578,339

76.1%


Operating expenses

Research and development

421,447

(9,859)

(1)

411,588

Sales and marketing

622,221

(18,312)

(1)

603,909

General and administrative

263,521

(15,904)

(1)

247,617

Amortization of acquired customer-based intangible assets

216,544

(216,544)

(2)

Special charges (recoveries)

1,748

(1,748)

(4)


GAAP-based income from operations / Non-GAAP-based income from operations

740,903

489,057

(5)

1,229,960

Other income (expense), net

61,434

(61,434)

(6)

Provision for (recovery of) income taxes

339,906

(188,931)

(7)

150,975


GAAP-based net income / Non-GAAP-based net income, attributable to OpenText

310,672

616,554

(8)

927,226


GAAP-based earnings per share / Non-GAAP-based earnings per share-diluted, attributable to OpenText

$

1.14

$

2.25

(8)

$

3.39

(1)

Adjustment relates to the exclusion of share-based compensation expense from our Non-GAAP-based operating expenses as this expense is excluded from our internal analysis of operating results.

(2)

Adjustment relates to the exclusion of amortization expense from our Non-GAAP-based operating expenses as the timing and frequency of amortization expense is dependent on our acquisitions and is hence excluded from our internal analysis of operating results.

(3)

GAAP-based and Non-GAAP-based gross profit stated in dollars and gross margin stated as a percentage of total revenue.

(4)

Adjustment relates to the exclusion of special charges (recoveries) from our Non-GAAP-based operating expenses as special charges (recoveries) are generally incurred in the periods relevant to an acquisition and include certain charges or recoveries that are not indicative or related to continuing operations, and are therefore excluded from our internal analysis of operating results.

(5)

GAAP-based and Non-GAAP-based income from operations stated in dollars.

(6)

Adjustment relates to the exclusion of other income (expense) from our Non-GAAP-based operating expenses as other income (expense) generally relates to the transactional impact of foreign exchange and is generally not indicative or related to continuing operations and is therefore excluded from our internal analysis of operating results. Other income (expense) also includes our share of income (losses) from our holdings in investments as a limited partner. We do not actively trade equity securities in these privately held companies nor do we plan our ongoing operations based around any anticipated fundings or distributions from these investments. We exclude gains and losses on these investments as we do not believe they are reflective of our ongoing business and operating results.

(7)

Adjustment relates to differences between the GAAP-based tax provision rate of approximately 52% and a Non-GAAP-based tax rate of approximately 14%; these rate differences are due to the income tax effects of items that are excluded for the purpose of calculating Non-GAAP-based adjusted net income. Such excluded items include amortization, share-based compensation, special charges (recoveries) and other income (expense), net. Also excluded are tax benefits/expense items unrelated to current period income such as changes in reserves for tax uncertainties and valuation allowance reserves, and “book to return” adjustments for tax return filings and tax assessments. Included is the amount of net tax benefits arising from the internal reorganization that occurred in Fiscal 2017 assumed to be allocable to the current period based on the forecasted utilization period. In arriving at our Non-GAAP-based tax rate of approximately 14%, we analyzed the individual adjusted expenses and took into consideration the impact of statutory tax rates from local jurisdictions incurring the expense. The GAAP-based tax provision rate for the year ended June 30, 2021 includes the income tax provision charge from the IRS settlement partially offset by a tax benefit from the release of unrecognized tax benefits due to the conclusion of relevant tax audits that was recognized during the second quarter of Fiscal 2021.

(8)

  Reconciliation of GAAP-based net income to Non-GAAP-based net income:

 


Year Ended June 30, 2021


Per share diluted

GAAP-based net income, attributable to OpenText

$

310,672

$

1.14

Add:

Amortization

435,340

1.59

Share-based compensation

51,969

0.19

Special charges (recoveries)

1,748

0.01

Other (income) expense, net

(61,434)

(0.22)

GAAP-based provision for (recovery of) income taxes

339,906

1.23

Non-GAAP-based provision for income taxes

(150,975)

(0.55)

Non-GAAP-based net income, attributable to OpenText

$

927,226

$

3.39

 


Reconciliation of Adjusted EBITDA


Year Ended June 30, 2021

GAAP-based net income, attributable to OpenText

$

310,672

Add:

Provision for (recovery of) income taxes

339,906

Interest and other related expense, net

151,567

Amortization of acquired technology-based intangible assets

218,796

Amortization of acquired customer-based intangible assets

216,544

Depreciation

85,265

Share-based compensation

51,969

Special charges (recoveries)

1,748

Other (income) expense, net

(61,434)

Adjusted EBITDA

$

1,315,033

GAAP-based net income margin

9.2

%

Adjusted EBITDA margin

38.8

%

 


Reconciliation of Free cash flows


Year Ended June 30, 2021

GAAP-based cash flows provided by operating activities

$

876,120

Add:

Capital expenditures (1)

(63,675)

Free cash flows

$

812,445


(1) Defined as “Additions of property and equipment” in the Consolidated Statements of Cash Flows.

 



Reconciliation of selected GAAP-based measures to Non-GAAP-based measures



for the three months ended March 31, 2021



(In thousands, except for per share data)


Three Months Ended March 31, 2021


GAAP-based


Measures 


GAAP-based Measures


% of Total Revenue


Adjustments 


Note


Non-GAAP-based


Measures 


Non-GAAP-based Measures


% of Total Revenue


Cost of revenues

Cloud services and subscriptions

$

123,729

$

(505)

(1)

$

123,224

Customer support

30,953

(464)

(1)

30,489

Professional service and other

50,321

(684)

(1)

49,637

Amortization of acquired technology-based intangible assets

53,453

(53,453)

(2)


GAAP-based gross profit and gross margin (%) /


Non-GAAP-based gross profit and gross margin (%)

571,665

68.6%

55,106

(3)

626,771

75.2%


Operating expenses

Research and development

110,071

(2,146)

(1)

107,925

Sales and marketing

158,687

(4,580)

(1)

154,107

General and administrative

71,548

(3,978)

(1)

67,570

Amortization of acquired customer-based intangible assets

54,156

(54,156)

(2)

Special charges (recoveries)

2,846

(2,846)

(4)


GAAP-based income from operations / Non-GAAP-based income from operations

152,396

122,812

(5)

275,208

Other income (expense), net

8,283

(8,283)

(6)

Provision for (recovery of) income taxes

31,818

1,485

(7)

33,303


GAAP-based net income / Non-GAAP-based net income, attributable to OpenText

91,490

113,044

(8)

204,534


GAAP-based earnings per share / Non-GAAP-based earnings per share-diluted, attributable to OpenText

$

0.33

$

0.42

(8)

$

0.75

(1)

Adjustment relates to the exclusion of share-based compensation expense from our Non-GAAP-based operating expenses as this expense is excluded from our internal analysis of operating results.

(2)

Adjustment relates to the exclusion of amortization expense from our Non-GAAP-based operating expenses as the timing and frequency of amortization expense is dependent on our acquisitions and is hence excluded from our internal analysis of operating results.

(3)

GAAP-based and Non-GAAP-based gross profit stated in dollars and gross margin stated as a percentage of total revenue.

(4)

Adjustment relates to the exclusion of special charges (recoveries) from our Non-GAAP-based operating expenses as special charges (recoveries) are generally incurred in the periods relevant to an acquisition and include certain charges or recoveries that are not indicative or related to continuing operations, and are therefore excluded from our internal analysis of operating results.

(5)

GAAP-based and Non-GAAP-based income from operations stated in dollars.

(6)

Adjustment relates to the exclusion of other income (expense) from our Non-GAAP-based operating expenses as other income (expense) generally relates to the transactional impact of foreign exchange and is generally not indicative or related to continuing operations and is therefore excluded from our internal analysis of operating results. Other income (expense) also includes our share of income (losses) from our holdings in investments as a limited partner. We do not actively trade equity securities in these privately held companies nor do we plan our ongoing operations based around any anticipated fundings or distributions from these investments. We exclude gains and losses on these investments as we do not believe they are reflective of our ongoing business and operating results.

(7)

Adjustment relates to differences between the GAAP-based tax provision rate of approximately 26% and a Non-GAAP-based tax rate of approximately 14%; these rate differences are due to the income tax effects of items that are excluded for the purpose of calculating Non-GAAP-based adjusted net income. Such excluded items include amortization, share-based compensation, special charges (recoveries) and other income (expense), net. Also excluded are tax benefits/expense items unrelated to current period income such as changes in reserves for tax uncertainties and valuation allowance reserves, and “book to return” adjustments for tax return filings and tax assessments. Included is the amount of net tax benefits arising from the internal reorganization that occurred in Fiscal 2017 assumed to be allocable to the current period based on the forecasted utilization period. In arriving at our Non-GAAP-based tax rate of approximately 14%, we analyzed the individual adjusted expenses and took into consideration the impact of statutory tax rates from local jurisdictions incurring the expense.

(8)

Reconciliation of GAAP-based net income to Non-GAAP-based net income:

 


Three Months Ended March 31, 2021


Per share diluted

GAAP-based net income, attributable to OpenText

$

91,490

$

0.33

Add:

Amortization

107,609

0.39

Share-based compensation

12,357

0.05

Special charges (recoveries)

2,846

0.01

Other (income) expense, net

(8,283)

(0.03)

GAAP-based provision for (recovery of) income taxes

31,818

0.12

Non-GAAP-based provision for income taxes

(33,303)

(0.12)

Non-GAAP-based net income, attributable to OpenText

$

204,534

$

0.75

 


Reconciliation of Adjusted EBITDA


Three Months Ended March 31, 2021

GAAP-based net income, attributable to OpenText

$

91,490

Add:

Provision for (recovery of) income taxes

31,818

Interest and other related expense, net

37,333

Amortization of acquired technology-based intangible assets

53,453

Amortization of acquired customer-based intangible assets

54,156

Depreciation

21,961

Share-based compensation

12,357

Special charges (recoveries)

2,846

Other (income) expense, net

(8,283)

Adjusted EBITDA

$

297,131

GAAP-based net income margin

11.0

%

Adjusted EBITDA margin

35.7

%

 


Reconciliation of Free cash flows


Three Months Ended March 31, 2021

GAAP-based cash flows provided by operating activities

$

63,572

Add:

Capital expenditures (1)

(13,311)

Free cash flows

$

50,261


(1) Defined as “Additions of property and equipment” in the Consolidated Statements of Cash Flows.

 





Reconciliation of selected GAAP-based measures to Non-GAAP-based measures



for the three months ended June 30, 2020



(In thousands, except for per share data)


Three Months Ended June 30, 2020


GAAP-based


Measures 


GAAP-based Measures


% of Total Revenue


Adjustments 


Note


Non-GAAP-based


Measures 


Non-GAAP-based Measures


% of Total Revenue


Cost of revenues

Cloud services and subscriptions

$

116,569

$

(490)

(1)

$

116,079

Customer support

32,568

(310)

(1)

32,258

Professional service and other

48,435

(377)

(1)

48,058

Amortization of acquired technology-based intangible assets

59,719

(59,719)

(2)


GAAP-based gross profit and gross margin (%) /


Non-GAAP-based gross profit and gross margin (%)

565,917

68.5

%

60,896

(3)

626,813

75.8

%


Operating expenses

Research and development

100,766

(1,590)

(1)

99,176

Sales and marketing

152,882

(2,575)

(1)

150,307

General and administrative

62,574

(2,660)

(1)

59,914

Amortization of acquired customer-based intangible assets

58,998

(58,998)

(2)

Special charges (recoveries)

75,849

(75,849)

(4)


GAAP-based income from operations / Non-GAAP-based income from operations

91,199

202,568

(5)

293,767

Other income (expense), net

7,790

(7,790)

(6)

Provision for (recovery of) income taxes

32,037

3,416

(7)

35,453


GAAP-based net income / Non-GAAP-based net income, attributable to OpenText

26,392

191,362

(8)

217,754


GAAP-based earnings per share / Non-GAAP-based earnings per share-diluted, attributable to OpenText

$

0.10

$

0.70

(8)

$

0.80

(1)

Adjustment relates to the exclusion of share-based compensation expense from our Non-GAAP-based operating expenses as this expense is excluded from our internal analysis of operating results.

(2)

Adjustment relates to the exclusion of amortization expense from our Non-GAAP-based operating expenses as the timing and frequency of amortization expense is dependent on our acquisitions and is hence excluded from our internal analysis of operating results.

(3)

GAAP-based and Non-GAAP-based gross profit stated in dollars and gross margin stated as a percentage of total revenue.

(4)

Adjustment relates to the exclusion of special charges (recoveries) from our Non-GAAP-based operating expenses as special charges (recoveries) are generally incurred in the periods relevant to an acquisition and include certain charges or recoveries that are not indicative or related to continuing operations, and are therefore excluded from our internal analysis of operating results.

(5)

GAAP-based and Non-GAAP-based income from operations stated in dollars.

(6)

Adjustment relates to the exclusion of other income (expense) from our Non-GAAP-based operating expenses as other income (expense) generally relates to the transactional impact of foreign exchange and is generally not indicative or related to continuing operations and is therefore excluded from our internal analysis of operating results. Other income (expense) also includes our share of income (losses) from our holdings in investments as a limited partner. We do not actively trade equity securities in these privately held companies nor do we plan our ongoing operations based around any anticipated fundings or distributions from these investments. We exclude gains and losses on these investments as we do not believe they are reflective of our ongoing business and operating results.

(7)

Adjustment relates to differences between the GAAP-based tax provision rate of approximately 55% and a Non-GAAP-based tax rate of approximately 14%; these rate differences are due to the income tax effects of items that are excluded for the purpose of calculating Non-GAAP-based adjusted net income. Such excluded items include amortization, share-based compensation, special charges (recoveries) and other income (expense), net. Also excluded are tax benefits/expense items unrelated to current period income such as changes in reserves for tax uncertainties and valuation allowance reserves, and “book to return” adjustments for tax return filings and tax assessments. Included is the amount of net tax benefits arising from the internal reorganization that occurred in Fiscal 2017 assumed to be allocable to the current period based on the forecasted utilization period. In arriving at our Non-GAAP-based tax rate of approximately 14%, we analyzed the individual adjusted expenses and took into consideration the impact of statutory tax rates from local jurisdictions incurring the expense.

(8)

Reconciliation of GAAP-based net income to Non-GAAP-based net income:

 


Three Months Ended June 30, 2020


Per share diluted

GAAP-based net income, attributable to OpenText

$

26,392

$

0.10

Add:

Amortization

118,717

0.44

Share-based compensation

8,002

0.03

Special charges (recoveries)

75,849

0.28

Other (income) expense, net

(7,790)

(0.03)

GAAP-based provision for (recovery of) income taxes

32,037

0.12

Non-GAAP-based provision for income taxes

(35,453)

(0.14)

Non-GAAP-based net income, attributable to OpenText

$

217,754

$

0.80

 


Reconciliation of Adjusted EBITDA


Three Months Ended June 30, 2020

GAAP-based net income, attributable to OpenText

$

26,392

Add:

Provision for (recovery of) income taxes

32,037

Interest and other related expense, net

40,529

Amortization of acquired technology-based intangible assets

59,719

Amortization of acquired customer-based intangible assets

58,998

Depreciation

23,649

Share-based compensation

8,002

Special charges (recoveries)

75,849

Other (income) expense, net

(7,790)

Adjusted EBITDA

$

317,385

GAAP-based net income margin

3.2

%

Adjusted EBITDA margin

38.4

%

 


Reconciliation of Free cash flows


Three Months Ended June 30, 2020

GAAP-based cash flows provided by operating activities

$

280,250

Add:

Capital expenditures (1)

(17,704)

Free cash flows

$

262,546


(1) Defined as “Additions of property and equipment” in the Consolidated Statements of Cash Flows.

 



Reconciliation of selected GAAP-based measures to Non-GAAP-based measures



for the year ended June 30, 2020



(In thousands, except for per share data)


Year Ended June 30, 2020


GAAP-based


Measures 


GAAP-based Measures


% of Total Revenue


Adjustments 


Note


Non-GAAP-based


Measures 


Non-GAAP-based Measures


% of Total Revenue


Cost of revenues

Cloud services and subscriptions

$

449,940

$

(1,642)

(1)

$

448,298

Customer support

123,894

(1,207)

(1)

122,687

Professional service and other

212,903

(1,294)

(1)

211,609

Amortization of acquired technology-based intangible assets

205,717

(205,717)

(2)


GAAP-based gross profit and gross margin (%) /


Non-GAAP-based gross profit and gross margin (%)

2,105,961

67.7

%

209,860

(3)

2,315,821

74.5

%


Operating expenses

Research and development

370,411

(5,309)

(1)

365,102

Sales and marketing

585,044

(9,335)

(1)

575,709

General and administrative

237,532

(10,745)

(1)

226,787

Amortization of acquired customer-based intangible assets

219,559

(219,559)

(2)

Special charges (recoveries)

100,428

(100,428)

(4)


GAAP-based income from operations / Non-GAAP-based income from operations

503,529

555,236

(5)

1,058,765

Other income (expense), net

(11,946)

11,946

(6)

Provision for (recovery of) income taxes

110,837

16,897

(7)

127,734


GAAP-based net income / Non-GAAP-based net income, attributable to OpenText

234,225

550,285

(8)

784,510


GAAP-based earnings per share / Non-GAAP-based earnings per share-diluted, attributable to OpenText

$

0.86

$

2.03

(8)

$

2.89

(1)

Adjustment relates to the exclusion of share-based compensation expense from our Non-GAAP-based operating expenses as this expense is excluded from our internal analysis of operating results.

(2)

Adjustment relates to the exclusion of amortization expense from our Non-GAAP-based operating expenses as the timing and frequency of amortization expense is dependent on our acquisitions and is hence excluded from our internal analysis of operating results.

(3)

GAAP-based and Non-GAAP-based gross profit stated in dollars and gross margin stated as a percentage of total revenue.

(4)

Adjustment relates to the exclusion of special charges (recoveries) from our Non-GAAP-based operating expenses as special charges (recoveries) are generally incurred in the periods relevant to an acquisition and include certain charges or recoveries that are not indicative or related to continuing operations, and are therefore excluded from our internal analysis of operating results.

(5)

GAAP-based and Non-GAAP-based income from operations stated in dollars.

(6)

Adjustment relates to the exclusion of other income (expense) from our Non-GAAP-based operating expenses as other income (expense) generally relates to the transactional impact of foreign exchange and is generally not indicative or related to continuing operations and is therefore excluded from our internal analysis of operating results. Other income (expense) also includes our share of income (losses) from our holdings in investments as a limited partner. We do not actively trade equity securities in these privately held companies nor do we plan our ongoing operations based around any anticipated fundings or distributions from these investments. We exclude gains and losses on these investments as we do not believe they are reflective of our ongoing business and operating results.

(7)

Adjustment relates to differences between the GAAP-based tax provision rate of approximately 32% and a Non-GAAP-based tax rate of approximately 14%; these rate differences are due to the income tax effects of items that are excluded for the purpose of calculating Non-GAAP-based adjusted net income. Such excluded items include amortization, share-based compensation, special charges (recoveries) and other income (expense), net. Also excluded are tax benefits/expense items unrelated to current period income such as changes in reserves for tax uncertainties and valuation allowance reserves, and “book to return” adjustments for tax return filings and tax assessments. Included is the amount of net tax benefits arising from the internal reorganization that occurred in Fiscal 2017 assumed to be allocable to the current period based on the forecasted utilization period. In arriving at our Non-GAAP-based tax rate of approximately 14%, we analyzed the individual adjusted expenses and took into consideration the impact of statutory tax rates from local jurisdictions incurring the expense.

(8)

Reconciliation of GAAP-based net income to Non-GAAP-based net income:

 


Year Ended June 30, 2020


Per share diluted

GAAP-based net income, attributable to OpenText

$

234,225

$

0.86

Add:

Amortization

425,276

1.56

Share-based compensation

29,532

0.11

Special charges (recoveries)

100,428

0.37

Other (income) expense, net

11,946

0.04

GAAP-based provision for (recovery of) income taxes

110,837

0.41

Non-GAAP-based provision for income taxes

(127,734)

(0.46)

Non-GAAP-based net income, attributable to OpenText

$

784,510

$

2.89

 


Reconciliation of Adjusted EBITDA


Year Ended June 30, 2020

GAAP-based net income, attributable to OpenText

$

234,225

Add:

Provision for (recovery of) income taxes

110,837

Interest and other related expense, net

146,378

Amortization of acquired technology-based intangible assets

205,717

Amortization of acquired customer-based intangible assets

219,559

Depreciation

89,458

Share-based compensation

29,532

Special charges (recoveries)

100,428

Other (income) expense, net

11,946

Adjusted EBITDA

$

1,148,080

GAAP-based net income margin

7.5

%

Adjusted EBITDA margin

36.9

%

 


Reconciliation of Free cash flows


Year Ended June 30, 2020

GAAP-based cash flows provided by operating activities

$

954,536

Add:

Capital expenditures (1)

(72,709)

Free cash flows

$

881,827


(1) Defined as “Additions of property and equipment” in the Consolidated Statements of Cash Flows.

 



(3)

The following tables provide a composition of our major currencies for revenue and expenses, expressed as a percentage, for the three months and year ended June 30, 2021 and 2020:


Three Months Ended June 30, 2021


Three Months Ended June 30, 2020


Currencies


% of Revenue


% of Expenses(1)


% of Revenue


% of Expenses(1)

EURO

24

%

14

%

22

%

13

%

GBP

5

%

5

%

4

%

5

%

CAD

3

%

13

%

3

%

8

%

USD

60

%

53

%

63

%

57

%

Other

8

%

15

%

8

%

17

%

Total

100

%

100

%

100

%

100

%


Year Ended June 30, 2021


Year Ended June 30, 2020


Currencies


% of Revenue


% of Expenses(1)


% of Revenue


% of Expenses(1)

EURO

23

%

14

%

22

%

14

%

GBP

5

%

5

%

5

%

6

%

CAD

3

%

11

%

3

%

9

%

USD

61

%

54

%

61

%

55

%

Other

8

%

16

%

9

%

16

%

Total

100

%

100

%

100

%

100

%


(1)

Expenses include all cost of revenues and operating expenses included within the Consolidated Statements of Income, except for amortization of intangible assets, share-based compensation and special charges (recoveries).

 

Cision View original content:https://www.prnewswire.com/news-releases/opentext-reports-fourth-quarter-and-fiscal-year-2021-financial-results-301349782.html

SOURCE Open Text Corporation

Calyxt Reports Second Quarter 2021 Financial Results

Appointed Michael A. Carr as President and Chief Executive Officer

Expanded Commercial Potential of Proprietary Hemp Breeding Platform with Multiple Innovations, including “Pollen-Proof” (Seedless) Hemp and Genome Transformation

Sold More than 75% of 2020 Grain Crop to Date to Archers Daniels Midland (ADM) Generating $27 Million in Total Cash Since Sales Commenced in Q3 2020

Net Cash Used by Operating Activities Improved by $11.6 Million Year-Over-Year

Management to Host Conference Call Today at 4:30 p.m. ET

PR Newswire

ROSEVILLE, Minn., Aug. 5, 2021 /PRNewswire/ — Calyxt, Inc. (NASDAQ: CLXT), a plant-based technology company, today announced financial results for its second quarter ended June 30, 2021.

“We made significant progress in the second quarter, notably appointing Michael A. Carr as President and Chief Executive Officer where he will lead us in our efforts to advance the evolution of our plant-based technology platform,” said Yves Ribeill, Ph.D., Executive Chair. “Our scientific and technical teams have made important advances across our hemp breeding technologies. In addition to successfully transforming the hemp genome, we also added triploid breeding technology, allowing for the development of “pollen-proof”, seedless hemp. This is a significant innovation and marks the second step in our comprehensive approach to improving the hemp species and expanding its commercial potential.”

“I’m excited to be joining the Calyxt team as we advance our mission to utilize plants to generate innovative, sustainable, and high-value products for customers and partners,” said Mr. Carr. “The highly skilled team has built an impressive and unique plant-based technology platform. Calyxt has significant value to unlock through the commercialization of our product portfolio, proprietary technologies, and know-how. I look forward to working closely with the team to advance our exciting platform and realize this potential.”

Key accomplishments in the second quarter of 2021 and through the date of this release include: 

  • Appointed Michael A. Carr as its President, Chief Executive Officer, and member of its Board of Directors effective July 27, 2021. Mr. Carr brings more than 20 years of business, financial and operational leadership experience to Calyxt and will focus on advancing and monetizing Calyxt’s technologies. Most recently, he served as Vice President of M&A, Strategy, and Innovation at Darling Ingredients, Inc.
  • With the expansion of its hemp breeding platform, Calyxt is demonstrating industry leadership in modernizing the species. Calyxt has successfully transformed the genome and produced “pollen-proof” (seedless) hemp with its triploid breeding technology. Combined, Calyxt’s hemp advancements offer significant advantages in innovation, crop management, and harvest potential. More broadly, Calyxt can now deliver hemp products tailored for the benefit of both growers and consumers, who are increasingly looking for plant-based and sustainable foods, materials, cosmeceuticals, nutraceuticals, and more.
  • Completed the sale of more than 75% percent of the 2020 grain crop to date to ADM, with the remaining grain projected to be sold throughout 2021. This series of transactions, which began in the third quarter of 2020, has generated $27 million in total cash since sales commenced.
  • Net cash used by operating activities improved by $11.6 million from the same period a year ago driven primarily by an improvement in Calyxt’s working capital investment associated with the change to the go-to-market strategy for its soybean product line and a lower net loss in the period driven by a reduction in operating expenses following that change in go-to-market strategy.
  • Promoted Sarah Reiter to the newly created role of Chief Business Officer, effective May 1, 2021. In this role Ms. Reiter is responsible for all of Calyxt’s commercial activities, including securing strategic partners for the development and commercialization of products. She is also responsible for corporate communications and product marketing.


Go-To-Market Strategies and Current Development Pipeline

Calyxt’s baseline go-to-market strategies include product development agreements, product license arrangements, and technology licensing agreements. Calyxt intends to move its current soybean product to a product license go-to-market strategy in 2022 and is currently in discussions with potential licensors.

Calyxt has seven publicly disclosed products in development that have a target commercial planting year, and for which it is actively seeking partners in all cases but alfalfa, where it has executed a commercialization agreement with S&W Seed Company (Nasdaq: SANW). A summary as of June 30, 2021, is as follows:     


CROP


PRODUCT1


TARGET COMMERCIAL
PLANTING YEAR

Alfalfa

Improved Digestibility

2022

Wheat

High Fiber

2023

Soybean

High Oleic, Low Linolenic
(HOLL)

2023

Hemp

“Pollen-Proof” (Seedless) 

2023

Hemp

Stability for Food, Oil &
Fiber 

2024

Oat

Winter

2026

Soybean

High Saturated Fat
(Palm Alternative)

2026

1 The agronomic and functional quality of product candidates and the timing of development are subject to a variety of factors and risks, which are described in Calyxt’s filings with the Securities and Exchange Commission. 

Calyxt will selectively continue to develop the products in the table above to enable development and commercial agreements to be reached, and its baseline go-to-market strategies support modest capital requirements for these products. When commercialized by the licensors, the products are expected to deliver high margin royalty revenue streams.

Calyxt is also pursuing strategic product development opportunities. In these cases, Calyxt’s core strengths of research and product development are aligned with the commercialization and downstream execution capabilities of a potential partner. Calyxt anticipates that these partnerships will reduce its capital requirements for research and development, result in near-term cash inflow, and provide opportunities for additional revenue streams over time, including high margin milestone and royalty or license payments.

“As our R&D team continues to innovate our development pipeline based on Calyxt’s proprietary systems and advanced analytics platforms, the management team remains focused on the identification and development of high value customer- and partner-driven targets to expand the company’s potential commercial footprint,” said Dr. Ribeill.


Financial Results for the Three Months Ended June 30, 2021

  • Revenue was $11.9 million in the second quarter of 2021, an increase of $9.6 million, or 415 percent, from the second quarter of 2020. The increase was driven by the volume and mix of product sold in the quarter, as Calyxt sold seed and 25 percent of the 2020 grain crop in the second quarter of 2021 as compared to the second quarter of 2020, when it was selling soybean oil and meal. As of June 30, 2021, Calyxt had sold over 75 percent of the 2020 grain crop.
  • Cost of goods sold was $11.5 million in the second quarter of 2021, an increase of $6.2 million, or 117 percent, from the second quarter of 2020. The increase was driven by higher volumes of product sold and higher average prices paid for grain due to increases in commodity market prices for soybeans. These increases were partially offset by the benefits resulting from the move to sell grain compared to selling oil and meal, as well as a $2.9 million year-over-year decrease in net realizable value adjustments to inventory, as the year ago period included costs to write down excess seed inventory and also reflected the margin profile of selling soybean oil and meal compared to selling grain, and $0.5 million of unrealized commodity derivative gains from hedging contracts sold to convert fixed price grain inventory and fixed price forward purchase contracts to floating prices to link them to market, consistent with how it expects to sell the grain.
  • Gross margin was $0.4 million, or 3 percent, in the second quarter of 2021, an increase of $3.4 million or 112% percent from the second quarter of 2020. The improvement was primarily driven by the benefits resulting from the move to sell grain compared to selling oil and meal, as well as a $2.9 million year-over-year decrease in net realizable value adjustments to inventory as the year ago period included costs to write down excess seed inventory and also reflected the margin profile of selling soybean oil and meal compared to selling grain, and $0.5 million of unrealized commodity derivative gains from hedging contracts sold to convert fixed price grain inventory and fixed price forward purchase contracts to floating prices to link them to market, consistent with how it expects  to sell the grain.

Adjusted gross margin, a non-GAAP measure, was negative $1.2 million, or negative 10 percent, in the second quarter of 2021, compared to negative $0.8 million, or negative 34 percent, in the second quarter of 2020. The improvement on a percentage basis was driven by benefits resulting from the move to sell grain compared to selling oil and meal.

See below under the heading “Use of Non-GAAP Financial Information” for a discussion of adjusted gross margin and a reconciliation of gross margin, the most comparable GAAP measure, to adjusted gross margin.

  • Total operating expenses were $6.3 million in the second quarter of 2021, a decrease of $1.7 million, or 21 percent, from $8.0 million in the second quarter of 2020. The decrease was driven by lower personnel expenses as a result of cost reductions following the move to sell grain compared to selling oil and meal, as well as other reductions in operating expenses from the second quarter of 2020.
  • Net loss was $4.8 million in the second quarter of 2021, an improvement of $6.1 million, or 56 percent, from the second quarter of 2020. The improvement in net loss was driven by improved gross margins, reduced operating expenses, and the gain upon the extinguishment of Calyxt’s Payroll Protection Program (PPP) loan. Net loss per share was $0.13 in the second quarter of 2021, an improvement of $0.20 per share, or 61 percent, from the second quarter of 2020. The improvement in net loss per share was driven by the change in net loss and the year-over-year increase in the weighted average share count.

Adjusted net loss was $7.8 million in the second quarter of 2021, an improvement of $0.8 million, or 9 percent, from the second quarter of 2020. The improvement in adjusted net loss was driven by the benefits resulting from the move to sell grain compared to selling oil and meal and reductions in operating expenses. Adjusted net loss per share was $0.21 in the second quarter of 2021, an improvement of $0.05 per share, or 19 percent, from the second quarter of 2020. The improvement in adjusted net loss per share was driven by the change in adjusted net loss and the year-over-year increase in the weighted average share count.

See below under the heading “Use of Non-GAAP Financial Information” for a discussion of adjusted net loss and adjusted net loss per share, and reconciliations of net loss and net loss per share, the most comparable GAAP measures, to adjusted net loss and adjusted net loss per share. 

  • Adjusted EBITDA loss was $5.8 million in the second quarter of 2021, an improvement of $0.7 million, or 11 percent, from the second quarter of 2020. The improvement was driven by the benefits resulting from the move to sell grain compared to selling oil and meal and reductions in operating expenses.

See below under the heading “Use of Non-GAAP Financial Information” for a discussion of adjusted EBITDA and a reconciliation of net loss, the most comparable GAAP measure, to adjusted EBITDA.

  • Net cash used by operating activities was $1.8 million in the second quarter of 2021, an improvement of $11.6 million from the second quarter of 2020. The improvement was driven primarily by an improvement in working capital investment associated with the change in go-to-market strategy for the soybean product line and a lower net loss in the period driven by a reduction in operating expenses following that change in go-to-market strategy.
  • Cash, cash equivalents, and restricted cash totaled $18.5 million as of June 30, 2021.


CFO Summary

“In the second quarter, we realized an $11.6 million year over year improvement in cash flow from operations as a result of increased product sales, improved gross margins and cash performance in the period, including expense management. We believe our cash, cash equivalents, and restricted cash of $18.5 million will fund our operations into the second half of 2022,” said Bill Koschak, Calyxt’s Chief Financial Officer. 


Second Quarter 2021 Results Conference Call

Executive Chair Yves Ribeill, Ph.D., President and Chief Executive Officer Michael A. Carr, and Chief Financial Officer Bill Koschak will host a conference call discussing Calyxt’s results for the second quarter of 2021, followed by a question-and-answer session.  The conference call will be accompanied by a presentation, which can be viewed during the webcast or accessed via the investor relations section of Calyxt’s website here.

To access the call, please use the following information:

Date Thursday, August 5, 2021
Time: 4:30 p.m. EST, 1:30 p.m. PST
Toll Free dial-in number: +1 (877) 407-9747
Toll/International dial-in number: +1 (412) 902-0044
Conference ID: 13721585

Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. The conference call will also be broadcast live and available for replay via the investor relations section of the company’s website here. A replay of the webcast will be available for 30 days following the event.

A replay of the call will be available for one month following the conference.

Toll Free Replay Number: +1 (877) 660-6853
International Replay Number: +1 (201) 612-7415
Replay ID: 13721585

About Calyxt:

Calyxt (NASDAQ: CLXT) is a plant-based biotechnology platform company focused on delivering innovations that revolutionize how the world uses plants. Calyxt uses its advanced plant-based biotechnology platform to generate innovative, high-value, and sustainable materials and products for world-class and industry leading customers and partners. For more information, go to www.calyxt.com.

Calyxt Media Contact:

Patrick Milan, Chief Insights Officer
TUNHEIM
+1 (612) 695-1369
[email protected]

Calyxt Investor Relations Contact:

Heather Savelle, Managing Director
Sherri Spear, Managing Director
Argot Partners
+1 (212) 600-1902
[email protected]

USE OF NON-GAAP FINANCIAL INFORMATION

To supplement Calyxt’s audited financial results prepared in accordance with GAAP, it has prepared certain non-GAAP measures that include or exclude special items. These non-GAAP measures are not meant to be considered in isolation or as a substitute for financial information presented in accordance with GAAP and should be viewed as supplemental and in addition to financial information presented in accordance with GAAP. Investors are cautioned that there are material limitations associated with the use of non-GAAP financial measures. In addition, other companies may report similarly titled measures, but calculate them differently, which reduces their usefulness as a comparative measure. Management utilizes these non-GAAP metrics as performance measures in evaluating and making operational decisions regarding Calyxt’s business.

Calyxt presents adjusted gross margin, a non-GAAP measure that reflects adjustments necessary to present the underlying gross margin of our soybean product line, including (i) unrealized gains and losses associated with commodity derivatives entered into to hedge the change in value of fixed price grain inventories and fixed price forward purchase contracts that should be recognized in the future when the underlying inventory is sold, (ii) gains and losses from commodity derivatives realized in prior periods but associated with inventory sold in the current period, (iii) net realizable value adjustments to inventories occurring in the period, which otherwise would have been recognized in the future when the underlying inventory is sold, and (iv) net realizable value adjustments recognized in prior periods but associated with inventory sold in the current period.

Calyxt provides in the table below a reconciliation of gross margin, which is the most directly comparable GAAP financial measure, to adjusted gross margin. It provides adjusted gross margin because it believes that this non-GAAP financial metric provides investors with useful supplemental information at this stage of commercialization as the amounts being adjusted affect the period-to-period comparability of gross margins and financial performance.

The table below presents a reconciliation of gross margin to adjusted gross margin:


Three Months Ended
June 30,


Six Months Ended
June 30,


 In Thousands


2021


2020


2021


2020

Gross margin(GAAP measure)


$


353

$

(3,014)


$


(1,990)

$

(4,521)

Gross margin percentage


3


%

(131)

%


(12)

%

(97)

%

Non-GAAP adjustments:

Commodity derivative impact, net


(658)


(447)

Net realizable value adjustments to inventories


(859)

2,221


(72)

2,555


Adjusted gross margin


$


(1,164)

$

(793)


$


(2,509)

$

(1,966)


Adjusted gross margin percentage


(10)

%

(34)

%


(15)

%

(42)

%

Calyxt presents adjusted net loss, a non-GAAP measure, and define it as net loss including adjustments necessary to present the underlying gross margin of our soybean product line, including (i) unrealized gains and losses associated with commodity derivatives entered into to hedge the change in value of fixed price grain inventories and fixed price forward purchase contracts that should be recognized in the future when the underlying inventory is sold, (ii) gains and losses from commodity derivatives realized in prior periods but associated with inventory sold in the current period, (iii) net realizable value adjustments to inventories occurring in the period, which otherwise would have been recognized in the future when the underlying inventory is sold, and (iv) net realizable value adjustments recognized in prior periods but associated with inventory sold in the current period; and excluding  Section 16 officer transition expenses, the recapture of non-cash stock compensation primarily associated with the departure of Section 16 officers, the gain upon the extinguishment of Calyxt’s PPP loan, and non-operating expenses, which are primarily gains and losses on foreign exchange transactions and losses on the disposals of land, buildings, and equipment.

Calyxt provides in the table below a reconciliation of net loss, which is the most directly comparable GAAP financial measure, to adjusted net loss. It provides adjusted net loss because it believes that this non-GAAP financial metric provides investors with useful supplemental information at this stage of commercialization as the amounts being adjusted affect the period-to-period comparability of net losses and financial performance.

The table below presents a reconciliation of net loss to adjusted net loss: 


Three Months Ended
June 30,


Six Months Ended


June 30,


In Thousands


2021


2020


2021


2020

Net loss (GAAP measure)


$


(4,807)

$

(10,902)


$


(14,835)

$

(21,965)

Non-GAAP adjustments:

Commodity derivative impact, net


(658)


(447)

Net realizable value adjustments to inventories


(859)

2,221


(72)

2,555

Section 16 officer transition expenses


13

77


2,734

437

Recapture of non-cash stock compensation




(2,540)

(471)

Gain upon extinguishment of Payroll Protection
Program loan


(1,528)


(1,528)

Non-operating expenses


(6)

8


(5)

19


Adjusted net loss


$


(7,845)

$

(8,596)


$


(16,693)

$

(19,425)

Calyxt presents adjusted net loss per share, a non-GAAP measure, and define it as net loss per share including adjustments necessary to present the underlying gross margin of our soybean product line, including (i) unrealized gains and losses associated with commodity derivatives entered into to hedge the change in value of fixed price grain inventories and fixed price forward purchase contracts that should be recognized in the future when the underlying inventory is sold, (ii) gains and losses from commodity derivatives realized in prior periods but associated with inventory sold in the current period, (iii) net realizable value adjustments to inventories occurring in the period, which otherwise would have been recognized in the future when the underlying inventory is sold, and (iv) net realizable value adjustments recognized in prior periods but associated with inventory sold in the current period; and excluding Section 16 officer transition expenses, the recapture of  non-cash stock compensation primarily associated with the departure of Section 16 officers, the gain upon the extinguishment of Calyxt’s PPP loan, and non-operating expenses, which are primarily gains and losses on foreign exchange transactions and losses on the disposals of land, buildings, and equipment. 

Calyxt provides in the table below a reconciliation of net loss per share, which is the most directly comparable GAAP financial measure, to adjusted net loss per share. It provides adjusted net loss per share because it believes that this non-GAAP financial metric provides investors with useful supplemental information at this stage of commercialization as the amounts being adjusted affect the period-to-period comparability of net losses per share and financial performance.

The table below presents a reconciliation of net loss per share to adjusted net loss per share:


Three Months Ended
June 30,


Six Months Ended



June 30,


2021


2020


2021


2020

Net loss per share (GAAP measure)


$


(0.13)

$

(0.33)


$


(0.40)

$

(0.67)

Non-GAAP adjustments:

Commodity derivative impact, net


(0.02)


(0.01)

Net realizable value adjustments to inventories


(0.02)

0.07



0.08

Section 16 officer transition expenses




0.07

0.01

Recapture of non-cash stock compensation




(0.07)

(0.01)

Gain upon extinguishment of Payroll Protection
Program loan


(0.04)


(0.04)

Non-operating expenses






Adjusted net loss per share


$


(0.21)

$

(0.26)


$


(0.45)

$

(0.59)

Calyxt presents adjusted EBITDA, a non-GAAP measure, and define it as net loss excluding interest, net, depreciation and amortization expenses, non-cash stock-based compensation expenses including the recapture of non-cash stock compensation primarily associated with the departure of Section 16 officers, Section 16 officer transition expenses, the gain upon the extinguishment of Calyxt’s PPP loan, and non-operating expenses, which are primarily gains and losses on foreign exchange transactions and losses on the disposals of land, buildings, and equipment, and including adjustments necessary to present the underlying gross margin of our soybean product line, including (i) unrealized gains and losses associated with commodity derivatives entered into to hedge the change in value of fixed price grain inventories and fixed price forward purchase contracts that should be recognized in the future when the underlying inventory is sold, (ii) gains and losses from commodity derivatives realized in prior periods but associated with inventory sold in the current period, (iii) net realizable value adjustments to inventories occurring in the period, which otherwise would have been recognized in the future when the underlying inventory is sold, and (iv) net realizable value adjustments recognized in prior periods but associated with inventory sold in the current period.

Calyxt provides in the table below a reconciliation of net loss, which is the most directly comparable GAAP financial measure, to adjusted EBITDA. Because adjusted EBITDA excludes non-cash items and discrete or infrequently occurring items, it believes that adjusted EBITDA provides investors with useful supplemental information about the operational performance of Calyxt’s business and facilitates the period-to-period comparability of financial results where certain items may vary significantly independent of business performance.

The table below presents a reconciliation of net loss to adjusted EBITDA:


Three Months Ended
June 30,


Six Months Ended


June 30,


In Thousands


2021


2020


2021


2020

Net loss (GAAP measure)


$


(4,807)

$

(10,902)


$


(14,835)

$

(21,965)

Non-GAAP adjustments:

Interest, net


357

(154)


703

244

Depreciation and amortization expenses


595

452


1,180

904

Stock-based compensation expenses


1,079

1,797


(371)

3,068

Commodity derivative impact, net


(658)




(447)



Net realizable value adjustments to inventories


(859)

2,221


(72)

2,555

Section 16 officer transition expenses


13

77


2,734

437

Gain upon extinguishment of Payroll Protection
Program loan


(1,528)




(1,528)



Non-operating expenses


(6)

8


(5)

19


Adjusted EBITDA


$


(5,814)

$

(6,501)


$


(12,641)

$

(14,738)

Forward-Looking Statements

This communication contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as “anticipates,” “believes,” “continue,” “estimates,” “expects,” “targets,” “intends,” “may,” “might,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” or the negative of these terms and other similar terminology. Forward-looking statements in this press release include statements about the potential impact of the COVID-19 pandemic on our business and operating results; our future financial performance; product pipeline and development; our business model and principal strategy for commercialization and sales of commercial products; regulatory progression; potential collaborations, partnerships and licensing arrangements and their contribution to our financial results, cash usage, and growth strategies; and anticipated trends in our business. These and other forward-looking statements are predictions and projections about future events and trends based on our current expectations, objectives and intentions and premised on current assumptions. Our actual results, level of activity, performance, or achievements could be materially different than those expressed, implied, or anticipated by forward-looking statements due to a variety of factors, including, but not limited to: the severity and duration of the evolving COVID-19 pandemic and the resulting impact on macro-economic conditions; the impact of increased competition; disruptions at our key facilities; changes in customer preferences and market acceptance of our products; competition for collaboration partners and licensees and the successful execution of collaborations and licensing agreements; the impact of adverse events during development, including unsuccessful field trials or development trials or disruptions in seed production; the impact of improper handling of our product candidates by unaffiliated third parties during development, such as the improper aerial spraying of our high fiber wheat product candidate; failures by third-party contractors; inaccurate demand forecasting or milestone and royalty payment projections; the effectiveness of commercialization efforts by commercial partners or licensees; our ability to make grain sales on terms acceptable to us; the timing of our grain sales; our ability to collect accounts receivable; disruptions to supply chains, including transportation and storage functions; commodity price conditions; the impact of changes or increases in oversight and regulation; disputes or challenges regarding intellectual property; proliferation and continuous evolution of new technologies; management changes; dislocations in the capital markets; and other important factors discussed in Part I, Item 1A, “Risk Factors” of our Annual Report on Form 10-K and subsequent filings on Form 10-Q or Form 8-K with the U.S. Securities and Exchange Commission. Any forward-looking statements made by us are based only on information currently available to us when, and speak only as of the date, such statement is made. Except as otherwise required by securities and other applicable laws we do not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change.


CALYXT, INC.


CONSOLIDATED BALANCE SHEETS


(In Thousands, Except Par Value and Share Amounts)


June 30, 2021
(unaudited)


December 31,
2020


Assets

Current assets:

Cash and cash equivalents


$


17,489

$

17,299

Short-term investments



11,698

Restricted cash


393

393

Accounts receivable


3,994

4,887

Inventory


2,468

1,383

Prepaid expenses and other current assets


629

3,930

Total current assets


24,973

39,590

Non-current restricted cash


598

597

Land, buildings, and equipment


21,998

22,860

Other non-current assets


207

280


Total assets


$


47,776

$

63,327


Liabilities and stockholders’ equity

Current liabilities:

Accounts payable


$


2,183

$

929

Accrued expenses


2,326

2,891

Accrued compensation


2,093

1,950

Due to related parties


128

766

Current portion of financing lease obligations


380

364

Other current liabilities


46

45

Total current liabilities


7,156

6,945

Financing lease obligations


17,682

17,876

Long-term debt



1,518

Other non-current liabilities


1,042

113


Total liabilities


25,880

26,452


Stockholders’ equity:

Common stock, $0.0001 par value; 275,000,000 shares authorized; 37,305,625 shares issued and 37,205,473 shares outstanding as of June 30, 2021, and 37,165,196 shares issued and 37,065,044 shares outstanding as of December 31, 2020


4

4

Additional paid-in capital


204,663

204,807

Common stock in treasury, at cost; 100,152 shares as of June 30, 2021, and December 31, 2020


(1,043)

(1,043)

Accumulated deficit


(181,728)

(166,893)


Total stockholders’ equity


21,896

36,875


Total liabilities and stockholders’ equity


$


47,776

$

63,327

 

 

 


CALYXT, INC.


CONSOLIDATED STATEMENTS OF OPERATIONS


(Unaudited and in Thousands Except Shares and Per Share Amounts)


Three Months Ended
June 30,


Six Months Ended



June 30,


2021


2020


2021


2020

Revenue


$


11,880

$

2,307


$


16,282

$

4,684

Cost of goods sold


11,527

5,321


18,272

9,205

Gross margin


353

(3,014)


(1,990)

(4,521)

Operating expenses:

Research and development


2,844

2,825


5,894

5,612

Selling, general, and administrative


3,478

5,167


7,736

11,465

Management fees


15

42


45

104

Total operating expenses


6,337

8,034


13,675

17,181


Loss from operations


(5,984)

(11,048)


(15,665)

(21,702)

Gain upon extinguishment of Payroll Protection
Program loan


1,528


1,528

Interest, net


(357)

154


(703)

(244)

Non-operating expenses


6

(8)


5

(19)

Loss before income taxes


(4,807)

(10,902)


(14,835)

(21,965)

Income taxes




Net loss


$


(4,807)

$

(10,902)


$


(14,835)

$

(21,965)


Basic and diluted net loss per share


$


(0.13)

$

(0.33)


$


(0.40)

$

(0.67)


Weighted average shares outstanding – basic and diluted


37,199,349

33,039,338


37,168,018

33,013,739

 


CALYXT, INC.


CONSOLIDATED STATEMENTS OF CASH FLOWS


(Unaudited and in Thousands)


Six Months Ended June 30,


2021


2020


Operating activities

Net loss


$


(14,835)

$

(21,965)

Adjustments to reconcile net loss to net cash used by operating activities:

Gain upon extinguishment of Payroll Protection Program loan


(1,528)

Depreciation and amortization


1,180

904

Stock-based compensation


(371)

3,068

Changes in operating assets and liabilities:

Accounts receivable


893

(1,289)

Due to/from related parties


(638)

(598)

Inventory


(1,085)

(2,688)

Prepaid expenses and other current assets


3,301

(1,118)

Accounts payable


1,254

(505)

Accrued expenses


(555)

(546)

Accrued compensation


143

(888)

Other


992

(26)


Net cash used by operating activities


(11,249)

(25,651)


Investing activities

Sales and (purchases) of short-term investments, net


11,698

(29,942)

Purchases of land, buildings, and equipment


(307)

(525)


Net cash provided by (used by) investing activities


11,391

(30,467)


Financing activities

Proceeds from Payroll Protection Program loan



1,518

Repayments of financing lease obligations


(178)

(130)

Proceeds from the exercise of stock options


227


Net cash provided by financing activities


49

1,388

Net increase (decrease) in cash, cash equivalents, and restricted cash


191

(54,730)

Cash, cash equivalents, and restricted cash – beginning of period


18,289

60,038


Cash, cash equivalents, and restricted cash – end of period


$


18,480

$

5,308

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/calyxt-reports-second-quarter-2021-financial-results-301349810.html

SOURCE Calyxt, Inc.

CarParts.com Reports Record Second Quarter 2021 Results

Record Quarterly Sales of $157.5 million, up 32%

6th Consecutive Quarter of Year over Year Sales Growth

Net Income Growth of 32% to $2.1 million and Record Adjusted EBITDA of $8.3 million

PR Newswire

TORRANCE, Calif., Aug. 5, 2021 /PRNewswire/ — CarParts.com, Inc. (NASDAQ: PRTS), one of the leading e-commerce providers of automotive parts and accessories, is reporting results for the second quarter ended July 3, 2021.

Second Quarter 2021 Summary vs. Year-Ago Quarter 

  • Net sales increased 32% year over year to $157.5 million.
  • Gross profit increased 31% to $53.3 million, with gross margin down 40 basis points to 33.9% driven in part to continued pressure from inbound and outbound freight as well as a shift in mix in branded products, which typically carry a higher selling price but lower gross margin percentage.
  • Net income was $2.1 million or $0.04 per diluted share, compared to net income of $1.6 million or $0.03 per diluted share.
  • Record Adjusted EBITDA of $8.3 million vs. $5.6 million.
  • Announced $30 million in stock repurchase plan.
  • Management reiterates long term targets of 20-25% compounded revenue growth and 8-10% EBITDA margin.

Management Commentary

“We saw another record-breaking quarter with revenues of $157.5 million,” said Lev Peker, CEO of CarParts.com. “We also achieved a record breaking $8.3 million of Adjusted EBITDA.”

“A large contributor to our revenue growth was due to an increase in DC capacity since Grand Prairie was fully operational. I’m proud to announce that we are expanding the space there by 156k square feet and we have also signed a lease to open a new 180k square foot Jacksonville, Florida distribution center. Once these two facilities are added to our network, our total DC square footage will exceed 1.2 million square feet.”

“We are also announcing a share repurchase program of up to $30 million. The program gives us a flexible way to return value to our shareholders when we see unwarranted volatility in our stock and we intend to be opportunistic with repurchases. An important driver of our decision making will of course be the potential ROI of any dollar spent; whether it’s an investment into our shares, inventory, supply chain or technology.”

Second Quarter
2021
Financial Results

Net sales in the second quarter of 2021 were $157.5 million compared to $118.9 million in the year-ago quarter. The increase was primarily driven by the expanded capacity coming from our Grand Prairie distribution center and the additional product offering of branded inventory from our partner network.

Gross profit in the second quarter increased 31% to $53.3 million compared to $40.8 million in the second quarter last year, with gross margin down 40 bps to 33.9% compared to 34.3%. The decrease in gross margin was in part due to continued pressure from inbound and outbound freight as well as a shift in mix in branded products, which typically carry a higher selling price but lower gross margin percentage.

Total operating expenses in the second quarter were $51.0 million compared to $38.7 million in the second quarter last year in line with our growth in sales.

Net income in the second quarter increased to $2.1 million compared to $1.6 million in the second quarter last year. The increase was driven by the significant sales growth. 

Adjusted EBITDA in the second quarter increased to $8.3 million compared to $5.6 million in the year-ago quarter. The increase was driven by the significant sales growth. 

On July 3, 2021, the Company had no revolver debt, no outstanding trade letters of credit (“LCs”) and a cash balance of $33.1 million, compared to no revolver debt, no outstanding trade LCs and a $35.8 million cash balance at prior fiscal year-end January 2, 2021.

On July 27, 2021, the Company’s Board of Directors authorized a new stock repurchase program under which the Company may purchase up to $30 million of the Company’s common stock from time to time. The repurchases of common stock may be executed through open market purchases, block trades, the implementation of a 10b5-1 plan, and/or any other available methods. The amount and timing of repurchases will depend upon market conditions and other corporate considerations. The share repurchase program does not obligate the Company to acquire any particular amount of stock, and it may be terminated, modified, or suspended at any time at the Company’s discretion.

Conference Call

CarParts.com CEO Lev Peker and CFO/COO David Meniane will host a conference call today via an audio webcast on the Company’s website per the link below, followed by a question and answer period.

Date: Thursday, August 5, 2021
Time: 5:00 p.m. Eastern time (2:00 p.m. Pacific time)
Webcast: www.carparts.com/investor/news-events

To listen to the live call, please click the link above to access the webcast at least 5-10 minutes prior to the start time to register your name and organization. The audio webcast will be archived on the Company’s website at www.carparts.com/investor

If you are unable to join via the webcast, you may dial in to the call at 833-649-1138 (domestic) or 918-922-3112 (international) using access code 6871145. A telephone replay will also be available on the same day through May 17, 2021 at 855-859-2056 (domestic) or 404-537-3406 (international) using access code 6871145.

About CarParts.com, Inc.

With over 25 years of experience, and more than 50 million parts delivered, we’ve streamlined our website and sourcing network to better serve the way drivers get the parts they need. Utilizing the latest technologies and design principles, we’ve created an easy-to-use, mobile-friendly shopping experience that, alongside our own nationwide distribution network, cuts out the brick-and-mortar supply chain costs and provides quality parts at a budget-friendly price.

CarParts.com is headquartered in Torrance, California.

Non-GAAP Financial Measures

Regulation G, and other provisions of the Securities Exchange Act of 1934, as amended, define and prescribe the conditions for use of certain non-GAAP financial information. We provide “Adjusted EBITDA,” which is a non-GAAP financial measure. Adjusted EBITDA consists of net income (loss) before (a) interest expense, net; (b) income tax provision; (c) depreciation and amortization expense; (d) amortization of intangible assets; and (e) share-based compensation expense. A reconciliation of Adjusted EBITDA to net income (loss) is provided below.

The Company believes that this non-GAAP financial measure provides important supplemental information to management and investors. This non-GAAP financial measure reflects an additional way of viewing aspects of the Company’s operations that, when viewed with the GAAP results and the accompanying reconciliation to corresponding GAAP financial measures, provides a more complete understanding of factors and trends affecting the Company’s business and results of operations.

Management uses Adjusted EBITDA as one measure of the Company’s operating performance because it assists in comparing the Company’s operating performance on a consistent basis by removing the impact of stock compensation expense and the costs associated with the customs issue, as well as other items that we do not believe are representative of our ongoing operating performance. Internally, this non-GAAP measure is also used by management for planning purposes, including the preparation of internal budgets; for allocating resources to enhance financial performance; and for evaluating the effectiveness of operational strategies. The Company also believes that analysts and investors use Adjusted EBITDA as a supplemental measure to evaluate the ongoing operations of companies in our industry.

This non-GAAP financial measure is used in addition to and in conjunction with results presented in accordance with GAAP and should not be relied upon to the exclusion of GAAP financial measures. Management strongly encourages investors to review the Company’s consolidated financial statements in their entirety and to not rely on any single financial measure. Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures with other companies’ non-GAAP financial measures having the same or similar names. In addition, the Company expects to continue to incur expenses similar to the non-GAAP adjustments described above, and exclusion of these items from the Company’s non-GAAP measures should not be construed as an inference that these costs are all unusual, infrequent or non-recurring.

Safe Harbor Statement

This press release contains statements
which are based on management’s current expectations, estimates and projections about the Company’s business and its industry, as well as certain assumptions made by the Company. These statements are forward looking statements for the purposes of the safe harbor provided by Section 21E of the Securities Exchange Act of 1934, as amended and Section 27A of the Securities Act of 1933, as amended. Words such as “anticipates,” “could,” “expects,” “intends,” “plans,” “potential,” “believes,” “predicts,” “projects,” “seeks,” “estimates,” “may,” “will,” “would,” “will likely continue” and variations of these words or similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding our future operating results and financial condition, our potential growth and our ability to expand and improve our product offerings, and repurchases by us of outstanding shares of our common stock. We undertake no obligation to revise or update publicly any forward-looking statements for any reason. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various factors.

Important factors that may cause such a difference include, but are not limited to, competitive pressures, our dependence on search engines to attract customers, demand for the Company’s products, the online market and channel mix for aftermarket auto parts, the economy in general, increases in commodity and component pricing that would increase the Company’s product costs, the operating restrictions in its credit agreement, the weather, the impact of the customs issues and any other factors discussed in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including the Risk Factors contained in the Company’s Annual Report on Form 10–K and Quarterly Reports on Form 10–Q, which are available at www.carparts.com/investor and the SEC’s website at www.sec.gov
. You are urged to consider these factors carefully in evaluating the forward-looking statements in this release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. Unless otherwise required by law, the Company expressly disclaims any obligation to update publicly any forward-looking statements, whether as result of new information, future events or otherwise.

Investor Relations:

Ryan Lockwood, CFA
[email protected]

 

 

Summarized information for the periods presented is as follows (in millions):


Thirteen Weeks Ended


Thirteen Weeks Ended


Twenty-Six Weeks Ended


Twenty-Six Weeks Ended


July 3, 2021


June 27, 2020


July 3, 2021


June 27, 2020

Net sales

$

157.54

$

118.93

$

302.34

$

206.75

Gross profit

$

53.35

$

40.83

$

102.52

$

70.61

33.9

%

34.3

%

33.9

%

34.2

%

Operating expense

$

51.01

$

38.65

$

102.69

$

68.79

32.4

%

32.5

%

34.0

%

33.3

%

Net income (loss)

$

2.07

$

1.57

$

(0.65)

$

0.59

1.3

%

1.3

%

(0.2)

%

0.3

%

Adjusted EBITDA

$

8.35

$

5.56

$

11.91

$

9.86

5.3

%

4.7

%

3.9

%

4.8

%

 

 

The table below reconciles net income (loss) to Adjusted EBITDA for the periods presented (in thousands):


Thirteen Weeks Ended


Thirteen Weeks Ended


Twenty-Six Weeks Ended


Twenty-Six Weeks Ended


July 3, 2021


June 27, 2020


July 3, 2021


June 27, 2020

Net income (loss)

$

2,072

$

1,568

$

(650)

$

590

Depreciation & amortization

2,171

1,634

4,550

3,532

Amortization of intangible assets

27

25

55

50

Interest expense, net

263

490

512

1,149

Taxes

113

118

168

154

EBITDA

$

4,646

$

3,835

$

4,635

$

5,475

Stock compensation expense

$

3,699

$

1,722

7,272

4,385

Adjusted EBITDA

$

8,345

$

5,557

$

11,907

$

9,860

 

 


CARPARTS.COM, INC. AND SUBSIDIARIES




 


CONSOLIDATED STATEMENTS OF COMPREHENSIVE OPERATIONS

(Unaudited, in Thousands, Except Per Share Data)


Thirteen Weeks Ended


Twenty-Six Weeks Ended


July 3,


June 27,


July 3,


June 27,


2021


2020


2021


2020

Net sales

$

157,536

$

118,930

$

302,338

$

206,748

Cost of sales (1)

104,187

78,101

199,815

136,140

Gross profit

53,349

40,829

102,523

70,608

Operating expense

51,013

38,653

102,685

68,785

Income (loss) from operations

2,336

2,176

(162)

1,823

Other income (expense):

Other, net

116

3

197

74

Interest expense

(267)

(493)

(517)

(1,153)

Total other expense, net

(151)

(490)

(320)

(1,079)

Income (loss) before income taxes

2,185

1,686

(482)

744

Income tax provision

113

118

168

154

Net income (loss)

2,072

1,568

(650)

590

Other comprehensive gain (loss):

Foreign currency translation adjustments

16

(29)

30

(35)

Unrealized gain (loss) on deferred compensation trust assets

38

58

73

(37)

Total other comprehensive gain (loss)

54

29

103

(72)

Comprehensive income (loss)

$

2,126

$

1,597

$

(547)

$

518

Net income (loss) per share:

Basic net income (loss) per share

$

0.04

$

0.04

$

(0.01)

$

0.01

Diluted net income (loss) income per share

$

0.04

$

0.03

$

(0.01)

$

0.01

Weighted-average common shares outstanding:

Shares used in computation of basic net income (loss) per share

51,684

39,386

50,222

38,124

Shares used in computation of diluted net income (loss) per share

57,122

47,329

50,222

42,058

(1)     Excludes depreciation and amortization expense which is included in operating expense.

 

 


CARPARTS.COM, INC. AND SUBSIDIARIES

 


CONSOLIDATED BALANCE SHEETS

(Unaudited, In Thousands, Except Par and Liquidation Value)

 


July 3,


January 2,


2021


2021


ASSETS

Current assets:

Cash and cash equivalents

$

33,149

$

35,802

Accounts receivable, net

6,994

6,318

Inventory

113,964

89,316

Other current assets

6,401

7,939

Total current assets

160,508

139,375

Property and equipment, net

17,602

14,742

Right-of-use – assets – operating leases, net

15,889

17,507

Right-of-use – assets – finance leases, net

14,890

12,457

Other non-current assets

2,278

2,892

Total assets

$

211,167

$

186,973


LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities:

Accounts payable

$

60,741

$

45,302

Accrued expenses

15,814

18,190

Customer deposits

400

630

Right-of-use – obligation – operating, current

2,729

2,527

Right-of-use – obligation – finance, current

2,255

1,583

Other current liabilities

4,018

3,747

Total current liabilities

85,957

71,979

Right-of-use – obligation – operating, non-current

14,359

16,046

Right-of-use – obligation – finance, non-current

13,005

11,428

Other non-current liabilities

3,826

4,031

Total liabilities

117,147

103,484

Commitments and contingencies

Stockholders’ equity:

Common stock, $0.001 par value; 100,000 shares authorized; 52,184 and 48,091 shares issued and outstanding as of July 3, 2021 and January 2, 2021 (of which 2,525 are treasury stock)

55

51

Treasury stock

(7,146)

(7,146)

Additional paid-in capital

271,334

260,260

Accumulated other comprehensive loss

(112)

(215)

Accumulated deficit

(170,111)

(169,461)

Total stockholders’ equity

94,020

83,489

Total liabilities and stockholders’ equity

$

211,167

$

186,973

 

 


CARPARTS.COM, INC. AND SUBSIDIARIES

 


CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited, In Thousands)

 


Twenty-Six Weeks Ended


July 3,


June 27,


2021


2020


Operating activities

Net (loss) income

$

(650)

$

590

Adjustments to reconcile net (loss) income to net cash provided by operating activities:

Depreciation and amortization expense

4,550

3,532

Amortization of intangible assets

55

50

Share-based compensation expense

7,272

4,385

Stock awards issued for non-employee director service

12

12

Loss from disposition of assets

1

Amortization of deferred financing costs

9

9

Changes in operating assets and liabilities:

Accounts receivable

(676)

(2,609)

Inventory

(24,649)

(12,883)

Other current assets

1,316

(1,597)

Other non-current assets

540

(296)

Accounts payable and accrued expenses

12,883

32,055

Other current liabilities

42

1,671

Right-of-use obligation – operating leases – current

430

483

Right-of-use obligation – operating leases – long-term

(76)

(383)

Other non-current liabilities

(77)

148

Net cash provided by operating activities

981

25,168


Investing activities

Additions to property and equipment

(5,398)

(3,840)

Net cash used in investing activities

(5,398)

(3,840)


Financing activities

Borrowings from revolving loan payable

90

1,273

Payments made on revolving loan payable

(90)

(1,273)

Proceeds from notes payable

4,107

Payments of notes payable

(5,333)

Payments on finance leases

(990)

(315)

Statutory tax withholding payment for share-based compensation

(3)

(85)

Proceeds from exercise of stock options

2,779

2,893

Net cash provided by financing activities

1,786

1,267

Effect of exchange rate changes on cash

(22)

(8)

Net change in cash and cash equivalents

(2,653)

22,587

Cash and cash equivalents, beginning of period

35,802

2,273

Cash and cash equivalents, end of period

$

33,149

$

24,860

Supplemental disclosure of non-cash investing and financing activities:

Right-of-use operating asset acquired

$

17

$

9,065

Right-of-use finance asset acquired

$

3,629

$

385

Accrued asset purchases

$

1,954

$

665

Share-based compensation expense capitalized in property and equipment

$

1,018

$

155

Stock issued for services

$

389

$

Supplemental disclosure of cash flow information:

Cash paid during the period for income taxes

$

65

$

90

Cash paid during the period for interest

$

543

$

1,125

 

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/carpartscom-reports-record-second-quarter-2021-results-301349016.html

SOURCE CarParts.com, Inc.

Neurocrine Biosciences Announces Completion of Enrollment in Phase 3 KINECT-HD Study Evaluating Valbenazine for Chorea in Huntington Disease

– Top-Line Readout of Clinical Study Results Anticipated by the End of 2021

– Initiating Expanded Enrollment to New Participants in Open-Label Extension Study KINECT-HD2

PR Newswire

SAN DIEGO, Aug. 5, 2021 /PRNewswire/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX), in collaboration with the Huntington Study Group, today announced the completion of patient enrollment for its Phase 3 (KINECT-HD) clinical study evaluating the efficacy, safety and tolerability of valbenazine, a selective, orally active vesicular monoamine transporter 2 (VMAT2) inhibitor being investigated as a once-daily treatment in adults with chorea in Huntington disease. A top-line data readout of the clinical study results is anticipated by the end of 2021.

“This milestone reflects the progress that we have made in advancing valbenazine as a potential treatment for people living with chorea in Huntington disease and we look forward to sharing top-line results later this year,” said Eiry W. Roberts, M.D., Chief Medical Officer at Neurocrine Biosciences. “I’d like to thank our partners at the Huntington Study Group, the Clinical Trials Coordination Center at the University of Rochester, New York, the KINECT-HD investigative staff, and especially the patients and families for their commitment and perseverance in completing enrollment in the face of all the challenges posed by the pandemic.”

Participants who have completed KINECT-HD can enroll in KINECT-HD2, an open-label extension study to evaluate the long-term safety and tolerability of valbenazine for the treatment of chorea in Huntington disease. The KINECT-HD2 study is now also open to new patients who have not participated in the KINECT-HD study.

Huntington disease impacts an estimated 30,000 adults in the United States. Chorea, an involuntary movement disorder, in which people develop abnormal, abrupt or irregular movements, is one of the most common symptoms, affecting roughly 90% of those diagnosed. Current treatments available for chorea are associated with increased risk of depression and suicidality.

“We’re pleased to be part of these clinical studies and to see valbenazine move forward in its development as a potential therapy for people living with chorea in Huntington disease,” said Andrew Feigin, M.D., Chair of the Huntington Study Group. “We are grateful for our partnership with Neurocrine Biosciences and the possibility of improving the lives of people living with this condition.”

Valbenazine was discovered and developed by Neurocrine Biosciences to address the unmet medical needs of people suffering from hyperkinetic movement disorders and was approved by the United States Food and Drug Administration (FDA) in April 2017 for the treatment of adults with tardive dyskinesia. Neurocrine Biosciences is also investigating valbenazine as an adjunctive treatment for schizophrenia and for the treatment of dyskinesia due to cerebral palsy.

About KINECT-HD
KINECT-HD is a Phase 3, randomized, double-blind, placebo-controlled study designed to: evaluate the efficacy of valbenazine as a once-daily treatment to reduce chorea associated with Huntington disease (HD); evaluate the safety and tolerability of valbenazine in patients with HD; and evaluate the ability of wearable movement sensors to detect changes in physical activity (optional activity). The study enrolled adults 18 to 75 years of age who have been diagnosed with motor manifest HD and whom have sufficient chorea symptoms to meet study protocol criteria. For more information on this KINECT-HD study, please visit www.huntingtonstudygroup.org.

About KINECT-HD2
KINECT-HD2 is an open-label, extension study to evaluate the long-term safety and tolerability of valbenazine in patients with chorea in Huntington disease (HD). The 112-week study enrolls adults 18 to 75 years of age who have been diagnosed with motor manifest HD and whom have sufficient chorea symptoms to meet study protocol criteria. For more information on the KINECT-HD2 study, please visit clinicaltrials.gov.

About Chorea in Huntington Disease

Huntington disease (HD) is a hereditary progressive neurodegenerative disorder in which neurons within the brain break down, resulting in motor, cognitive and psychiatric symptoms. Symptoms generally appear between the ages of 30 to 50 and worsen over a 10- to 25-year period. Many people with HD experience chorea, a troublesome involuntary movement disorder, in which people develop abnormal, abrupt or irregular movements. Chorea can affect various body parts and interfere with speech, swallowing, posture and gait. HD is estimated to affect approximately 30,000 adults in the U.S., with more than 200,000 at risk of inheriting the disease. Current treatments available for chorea are associated with increased risk of depression and suicidality.

About Huntington Study Group
Founded in 1993 in Rochester, NY, the Huntington Study Group (HSG) is a not-for-profit organization comprised of the world’s first and largest collaborative network of experts in Huntington disease (HD). The mission of the HSG is seeking treatments that make a difference for those affected by HD. With more than 800 credentialed HD experts at over 130 HSG credentialed research sites worldwide, the HSG is a leader in conducting clinical trials for HD. The HSG also offers educational services like CME4HD™ for healthcare professionals and care providers on treating patients with HD. For more information, visit our website www.huntingtonstudygroup.org.

About Neurocrine Biosciences
Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company dedicated to discovering, developing and delivering life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The company’s diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson’s disease, endometriosis*, uterine fibroids* and clinical programs in multiple therapeutic areas. For nearly three decades, Neurocrine Biosciences has specialized in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. For more information, visit neurocrine.com, and follow the company on LinkedIn. (*in collaboration with AbbVie)

Neurocrine Biosciences Forward-Looking Statements
In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are: risks and uncertainties associated with valbenazine development for chorea in Huntington disease (HD), that valbenazine development activities may not be completed on time or at all; risks that valbenazine development activities may not be completed or may be delayed for regulatory or other reasons, may not be successful or replicate previous clinical trial results, may fail to demonstrate that valbenazine is safe, tolerable or effective in the chorea in Huntington disease (HD) population, or may not be predictive of real-world results or of results in subsequent clinical trials; risks that regulatory submissions may not occur or be submitted in a timely manner; risks that valbenazine may not obtain regulatory approval for chorea in Huntington disease (HD), or that the U.S. Food and Drug Administration or regulatory authorities outside the U.S. may make adverse decisions regarding valbenazine; risks that valbenazine may be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; risks associated with the Company’s dependence on third parties for development and manufacturing activities related to valbenazine; risks and uncertainties relating to competitive products and technological changes that may limit demand for valbenazine and other risks described in the Company’s periodic reports filed with the Securities and Exchange Commission, including without limitation the Company’s quarterly report on Form 10-Q for the quarter ended June 30, 2021. Neurocrine disclaims any obligation to update the statements contained in this press release after the date hereof.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-completion-of-enrollment-in-phase-3-kinect-hd-study-evaluating-valbenazine-for-chorea-in-huntington-disease-301349714.html

SOURCE Neurocrine Biosciences, Inc.

Nabriva Therapeutics Reports Second Quarter 2021 Financial Results and Provides a Corporate Update

-Revenues of $8.2 million driven by launch of own National Drug Code (NDC) for SIVEXTRO-

-Cash runway substantially through Q1 2022-

-Announced positive Phase 3 trial results for lefamulin in China, commercial rights assigned to Sumitomo Pharmaceuticals (Suzhou) Co., Ltd (SPC)-

-Conference call today at 4:30 p.m. Eastern Time-

DUBLIN, Ireland, Aug. 05, 2021 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced its financial results for the three months ended June 30, 2021 and provided a corporate update.

“We continued to build on our momentum during the recent quarter with the launch of our own SIVEXTRO NDC, and the announcement of positive results from the third successful pivotal trial for lefamulin which support a potential New Drug Application (NDA) in China. We have also extended our cash runway substantially through the first quarter of 2022 as a result of successfully renegotiating our principal debt repayment and activity from our “at the market” offering program during the second quarter,” said Ted Schroeder, Chief Executive Officer of Nabriva Therapeutics.

Mr. Schroeder added, “We saw our commercial efforts continue to gain traction in the community. Our full complement of sales representatives has now been in the field for two full quarters and we are seeing a steady increase in our in-person interactions with healthcare providers, which are now over 70%. The launch of our SIVEXTRO NDC is off to a strong start, with net sales of $6.9 million in the second quarter of 2021. We remain focused on establishing the benefits of XENLETA with healthcare providers to position us to seize on the opportunity for what may be a more normal community-acquired bacterial pneumonia (CABP) season beginning this fall.”

Mr. Schroeder continues, “We are extremely excited about the potential opportunity for lefamulin and for CABP patients in the greater China Region. The positive pivotal trial results for lefamulin in China further validate the effectiveness of lefamulin in treating CABP. We expect that our new partner in China, Sumitomo Pharmaceuticals (Suzhou), the Chinese affiliate of Sumitomo Dainippon Pharma, will file an NDA for lefamulin in China in the second half of 2021. We are looking forward to working with Sumitomo Pharmaceuticals (Suzhou), a well-established commercial partner, on the launch of lefamulin in China. This represents a meaningful financial opportunity, as our collaboration with Sumitomo Pharmaceuticals (Suzhou) provides for low double-digit royalties, and up to $86.0 million in remaining regulatory and commercial milestones.”

CORPORATE AND DEVELOPMENT UPDATES

  • On August 4, 2021, Nabriva renegotiated terms of its manufacturing agreement with Hovione Limited, the company’s contract manufacturer for XENLETA. Under the renegotiated terms, Nabriva extended the agreement to manufacture XENLETA until November 2030. The initial agreement was set to expire in 2025.
  • On June 2, 2021, Nabriva renegotiated terms of its loan agreement with Hercules Capital. Under the renegotiated terms, Nabriva extended the commencement of principal repayments from July 1, 2021 until at least April 1, 2022.
  • On June 2, 2021, Nabriva announced the appointment of Dr. Mark Corrigan and Ms. Lisa Dalton to the Board of Directors.
  • On May 25, 2021, Nabriva’s partner in China announced positive results in its Phase 3 clinical trial of lefamulin. Nabriva also agreed to the assignment of the commercial rights to lefamulin in China from Sinovant Sciences Co., Ltd. to Sumitomo Pharmaceuticals (Suzhou), an established commercial company in the greater China Region.
  • On April 12, 2021, Nabriva began exclusive distribution of SIVEXTRO under the Nabriva National Drug Code and now recognizes 100% of net product sales and related cost of product sales of SIVEXTRO in its results of operations.
  • On April 5, 2021, the U.S. Food and Drug Administration (FDA) granted Nabriva an extension for the re-submission of the NDA for CONTEPO to June 19, 2022. The extension of the re-submission timeline was granted due to the ongoing COVID-related travel restrictions that have impacted the FDA’s ability to conduct onsite inspections of foreign manufacturing facilities.

FINANCIAL RESULTS

Three Months Ended June 30, 2020 and 2021

  • Revenues increased by $7.8 million from $0.5 million for the three months ended June 30, 2020 to $8.2 million for the three months ended June 30, 2021, primarily due to a $7.0 million increase in product revenue, net of which $6.9 million was driven by SIVEXTRO, an increase of $0.8 million in collaboration revenues for the three months ended June 30, 2021, which includes $0.6 million related to the restructured China Region License Agreement, a portion of which is recognized over the estimated period the manufacturing collaboration and regulatory support will be provided to the contract counterparty, as well as $0.2 million of our share of revenues through April 11, 2021 associated with the SIVEXTRO distribution agreement.
  • Cost of product sales increased by $3.3 million from $0.4 million for the three months ended June 30, 2020 to $3.6 million for the three months ended June 30, 2021. The increase was primarily due to the launch of our own SIVEXTRO NDC on April 12, 2021.
  • Research and development expenses decreased by $0.7 million from $3.8 million for the three months ended June 30, 2020 to $3.2 million for the three months ended June 30, 2021. The decrease was primarily due to a $0.2 million decrease in stock-based compensation expense, a $0.4 million decrease in staff costs, and a $0.2 million decrease in research materials and purchased services, partly offset by a $0.1 million increase in consulting costs.
  • Selling, general and administrative expense increased by $2.1 million from $10.7 million for the three months ended June 30, 2020 to $12.9 million for the three months ended June 30, 2021. The increase was primarily due to a $4.4 million increase in advisory and external consultancy expenses primarily related to commercialization activities and professional service fees for the relaunch of XENLETA and SIVEXTRO, partly offset by a $1.1 million decrease in staff costs due to the reduction of headcount, a $0.3 million decrease in stock-based compensation expense, a $0.7 million decrease in legal fees and a $0.2 million decrease in infrastructure costs.
  • Net loss decreased $3.6 million from a $15.4 million loss for the three months ended June 30, 2020, compared to a $11.8 million loss for the three months ended June 30, 2021.

Six Months Ended June 30, 2020 and 2021

  • Revenues increased by $9.5 million from $1.3 million for the six months ended June 30, 2020 to $10.8 million for the six months ended June 30, 2021, primarily due to a $7.0 million increase in product revenue, net of which $6.9 million was driven by SIVEXTRO, as well as an increase of $2.7 million of collaboration revenues for the six months ended June 30, 2021, which includes $1.6 million related to the restructured China Region License Agreement, a portion of which is recognized over the estimated period the manufacturing collaboration and regulatory support will be provided to the contract counterparty, as well as $1.2 million of our share of revenues associated with the SIVEXTRO distribution agreement.
  • Cost of product sales increased by $3.3 million from $0.4 million for the six months ended June 30, 2020 to $3.7 million for the six months ended June 30, 2021. The increase was primarily due to the launch of our own SIVEXTRO NDC on April 12, 2021.
  • Research and development expenses decreased by $1.8 million from $8.8 million for the six months ended June 30, 2020 to $7.0 million for the six months ended June 30, 2021. The decrease was primarily due to a $0.5 million decrease in stock-based compensation expense, a $1.0 million decrease in staff costs and a $0.4 million decrease in research materials and purchased services.
  • Selling, general and administrative expense decreased by $1.9 million from $26.8 million for the six months ended June 30, 2020 to $24.9 million for the six months ended June 30, 2021. The decrease was primarily due to a $5.9 million decrease in staff costs due to the reduction of headcount, a $0.9 million decrease in stock-based compensation expense, a $0.7 million decrease in travel costs, a $0.8 million decrease in legal fees, and a $0.4 million decrease in infrastructure costs, partly offset by a $6.9 million increase in advisory and external consultancy expenses primarily related to commercialization activities and professional service fees for the relaunch of XENLETA and SIVEXTRO.
  • Net loss decreased $13.0 million from a $38.7 million loss for the six months ended June 30, 2020, compared to a $25.7 million loss for the six months ended June 30, 2021.
  • As of June 30, 2021, the Company had cash and cash equivalents of $61.3 million. Based on its current operating plans, the Company expects that its existing cash resources, will be sufficient to enable it to fund its operating expenses, debt service obligations and capital expenditure requirements substantially through the first quarter of 2022.

Please refer to our Annual Report on Forms 10-K for the fiscal year ended
December 31, 2020
and our Quarterly Report on Form 10-Q for the quarterly period ended
June 30, 2021
, filed with the U
.S. Securities and Exchange Commission, for additional information regarding the Company’s business and financial results.

Company to Host Conference Call

Nabriva’s management will host a conference call today at 4:30 p.m. ET to discuss the financial results and recent corporate highlights. The dial-in number for the conference call is (866) 811-8671 for domestic participants and (409) 981-0874 for international participants, with Conference ID # 6299497. A live webcast of the conference call can be accessed through the “Investors” tab on the Nabriva Therapeutics website at www.nabriva.com. A replay will be available on this website shortly after conclusion of the event for 90 days.

About Nabriva Therapeutics plc

Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA® (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP). Nabriva Therapeutics is also developing CONTEPO™ (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis. Nabriva entered into an exclusive agreement with subsidiaries of Merck & Co. Inc., Kenilworth, N.J., USA to market, sell and distribute SIVEXTRO® (tedizolid phosphate) in the United States and certain of its territories.

About XENLETA

XENLETA (lefamulin) is a first-in-class semi-synthetic pleuromutilin antibiotic for systemic administration in humans discovered and developed by the Nabriva Therapeutics team. It is designed to inhibit the synthesis of bacterial protein, which is required for bacteria to grow. XENLETA’s binding occurs with high affinity, high specificity and at molecular sites that are different than other antibiotic classes. Efficacy of XENLETA was demonstrated in two multicenter, multinational, double-blind, double-dummy, non-inferiority trials assessing a total of 1,289 patients with CABP. In these trials, XENLETA was compared with moxifloxacin and in one trial, moxifloxacin with and without linezolid. Patients who received XENLETA had similar rates of efficacy as those taking moxifloxacin alone or moxifloxacin plus linezolid. The most common adverse reactions associated with XENLETA included diarrhea, nausea, reactions at the injection site, elevated liver enzymes, and vomiting. For more information, please visit www.XENLETA.com.

About SIVEXTRO

SIVEXTRO (tedizolid phosphate) was approved by the U.S. Food and Drug Administration in 2014. It is indicated in adults and pediatric patients 12 years of age and older for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus group (including Streptococcus anginosus, Streptococcus intermedius and Streptococcus constellatus), and Enterococcus faecalis. To reduce the development of drug-resistant bacteria and maintain the effectiveness of SIVEXTRO and other antibacterial drugs, SIVEXTRO should be used only to treat ABSSSI that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for Nabriva Therapeutics, including but not limited to statements about its ability to successfully commercialize XENLETA for the treatment of CABP, including the managed care coverage for XENLETA, the distribution and promotion of SIVEXTRO for the treatment of ABSSSI, the development of CONTEPO for Complicated Urinary Tract Infections (cUTI), the expansion of its commercial sales force, the clinical utility of XENLETA for CABP, SIVEXTRO for ABSSSI and of CONTEPO for cUTI, the impact on gross sales revenue from the recognition of SIVEXTRO sales in its results of operations, the impact of macro events on sales of SIVEXTRO and XENLETA, plans for and timing of the review of regulatory filings for XENLETA and CONTEPO, efforts to bring CONTEPO to market, the market opportunity for and the potential market acceptance of XENLETA for CABP, SIVEXTRO for ABSSSI and CONTEPO for cUTI, the development of XENLETA and CONTEPO for additional indications, the development of additional formulations of XENLETA and CONTEPO, plans for making lefamulin available in the European Union, Canada and China, the timing for and receipt of milestone and royalty payments under its license agreement with Sumitomo Pharmaceuticals (Suzhou), plans to pursue research and development of other product candidates, plans to pursue business development initiatives, expectations regarding the ability of customers to satisfy demand for XENLETA with their existing inventory, expectations regarding the impact of the interruptions resulting from COVID-19 on its business, the sufficiency of Nabriva Therapeutics’ existing cash resources and its expectations regarding anticipated revenues from product sales and how far into the future its existing cash resources will fund its ongoing operations and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “likely,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: Nabriva Therapeutics’ ability to successfully implement its commercialization plans for XENLETA and SIVEXTRO and whether market demand for XENLETA and SIVEXTRO is consistent with its expectations, Nabriva Therapeutics’ ability to build and maintain a sales force for XENLETA and SIVEXTRO, the content and timing of decisions made by the U.S. Food and Drug Administration and other regulatory authorities, the uncertainties inherent in the initiation and conduct of clinical trials, availability and timing of data from clinical trials, whether results of early clinical trials or studies in different disease indications will be indicative of the results of ongoing or future trials, uncertainties associated with regulatory review of clinical trials and applications for marketing approvals, the availability or commercial potential of CONTEPO for the treatment of cUTI, the extent of business interruptions resulting from the infection causing the COVID-19 outbreak or similar public health crises, the ability to retain and hire key personnel, the availability of adequate additional financing on acceptable terms or at all and such other important factors as are set forth in Nabriva Therapeutics’ annual and quarterly reports and other filings on file with the U.S. Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Nabriva Therapeutics’ views as of the date of this press release. Nabriva Therapeutics anticipates that subsequent events and developments will cause its views to change. However, while Nabriva Therapeutics may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Nabriva Therapeutics’ views as of any date subsequent to the date of this press release.

CONTACTS:

For Investors

Kim Anderson
Nabriva Therapeutics plc
[email protected]

For Media

Andrea Greif
Ogilvy
[email protected]
914-772-3027

Consolidated Balance Sheets (unaudited)

             
    As of   As of
(in thousands, except share data)      December 31, 2020      June 30, 2021
Assets            
Current assets:            
Cash and cash equivalents   $ 41,359     $ 61,140  
Restricted cash     231       180  
Short-term investments     16       16  
Accounts receivable, net and other receivables     3,909       11,576  
Inventory     5,823       10,113  
Prepaid expenses     5,880       11,595  
Total current assets     57,218       94,620  
Property, plant and equipment, net     768       355  
Intangible assets, net     80       54  
Other non-current assets     370       380  
Total assets   $ 58,436     $ 95,409  
Liabilities and stockholders´ equity            
Current liabilities:            
Current portion of long-term debt   $ 2,041     $ 1,823  
Accounts payable     2,889       1,582  
Accrued expense and other current liabilities     12,844       15,243  
Deferred revenue     750       563  
Total current liabilities     18,524       19,211  
Non-current liabilities            
Long-term debt     5,686       6,046  
Other non-current liabilities     1,091       951  
Total non-current liabilities     6,777       6,997  
Total liabilities     25,301       26,208  
Stockholders’ Equity:            
Ordinary shares, nominal value $0.01, 100,000,000 ordinary shares authorized at June 30, 2021; 21,078,781 and 49,737,552 issued and outstanding at December 31, 2020 and June 30, 2021, respectively     211       497  
Preferred shares, par value $0.01, 100,000,000 shares authorized at June 30, 2021; None issued and outstanding            
Additional paid in capital     579,123       640,638  
Accumulated other comprehensive income     27       27  
Accumulated deficit     (546,226 )     (571,961 )
Total stockholders’ equity     33,135       69,201  
Total liabilities and stockholders’ equity   $ 58,436     $ 95,409  



Consolidated Statements of Operations (unaudited)

                         
    Three Months Ended   Six Months Ended
    June 30,    June 30, 
(in thousands, except share and per share data)      2020
     2021
     2020
     2021
Revenues:                            
Product revenue, net   $ (48 )   $ 6,940     $ 108     $ 7,070  
Collaboration revenue     7       813       152       2,815  
Research premium and grant revenue     528       490       1,016       887  
Total revenue     487       8,243       1,276       10,772  
Operating expenses:                        
Cost of product sales     (368 )     (3,621 )     (376 )     (3,683 )
Research and development expenses     (3,831 )     (3,150 )     (8,775 )     (7,018 )
Selling, general and administrative expenses     (10,741 )     (12,854 )     (26,766 )     (24,901 )
Total operating expenses     (14,940 )     (19,625 )     (35,917 )     (35,602 )
Loss from operations     (14,453 )     (11,382 )     (34,641 )     (24,830 )
Other income (expense):                        
Other income (expense), net     (634 )     470       164       348  
Interest income     16       5       80       6  
Interest expense     (251 )     (241 )     (1,275 )     (463 )
Loss on extinguishment of debt                 (2,757 )      
Loss before income taxes     (15,322 )     (11,148 )     (38,429 )     (24,939 )
Income tax benefit (expense)     (119 )     (606 )     (271 )     (796 )
Net loss   $ (15,441 )   $ (11,754 )   $ (38,700 )   $ (25,735 )
                         
Loss per share                              
Basic and diluted ($ per share)   $ (1.37 )   $ (0.29 )   $ (3.73 )   $ (0.77 )
Weighted average number of shares:                        
Basic and diluted     11,277,825       40,573,848       10,368,670       33,532,837  



Condensed Consolidated Statements of Cash Flows (unaudited)

                 
        Six Months Ended

June 30,
(in thousands)       2020    2021 
Net cash provided by (used in):            
Operating activities       $ (45,372 )   $ (40,200 )
Investing activities       (248 )   (69 )
Financing activities       9,168     60,156  
Effects of exchange rate changes on the balance of cash held in foreign currencies       (70 )   (157 )
Net decrease (increase) in cash and cash equivalents and restricted cash       (36,522 )   19,730  
Cash and cash equivalents and restricted cash at beginning of period       86,411     41,590  
Cash and cash equivalents and restricted cash at end of period       $ 49,889     $ 61,320  

 



Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results

LEXINGTON, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today provided a business update and reported financial results for the quarter ended June 30, 2021.

“We have made substantial progress over the past quarter, including announcing our preliminary results from our Phase 2 clinical trial of KER-050,” said Jasbir S. Seehra, Ph.D., President and Chief Executive Officer. “We continue to make notable progress advancing our pipeline, and remain focused on the execution of our near-term development plans. In that regard, we remain on track to initiate several clinical trials for KER-050, KER-047 and KER-012 over the balance of 2021.”

Recent Corporate Highlights:

  • Executive leadership changes: In August 2021, the Company announced that Simon Cooper, M.B.B.S., has been appointed to serve as the Company’s Chief Medical Officer, effective as of August 2, 2021. Dr. Cooper succeeded Claudia Ordonez, M.D., who departed from the Chief Medical Officer position effective July 30, 2021. Dr. Ordonez will provide consulting services to the Company until September 15, 2021.
  • Issuance of Keros foundational U.S. patent: In May 2021, the United States Patent and Trademark Office issued U.S. Patent No. 11,013,785, which is a composition of matter patent directed to novel therapeutic proteins, including KER-050, that contains 20 claims and expires in November 2037.

Recent Program Highlights:

  • KER-050 for the treatment of ineffective hematopoiesis to address cytopenias

    • In June 2021, Keros announced preliminary results from Cohorts 1 and 2 (0.75 mg/kg and 1.5 mg/kg) of Part 1 of its Phase 2 clinical trial evaluating KER-050 in patients with myelodysplastic syndromes. Following Safety Review Committee recommendation, dosing for Cohort 3 of the trial was initiated at 2.5 mg/kg of KER-050, to be administered once every four weeks for 12 weeks.
    • The Company expects to report additional Part 1 data and initiate Part 2 of the trial by the end of 2021.

Second Quarter 2021 Financial Results

Keros reported a net loss of $15.6 million in the second quarter of 2021 as compared to a net loss of $10.8 million in the second quarter of 2020. The increase in net loss for the second quarter was largely due to increased research and development efforts as well as additional infrastructure expenses
to support our operations as a publicly traded company.

Research and development expenses were $10.0 million for the second quarter of 2021 as compared to $7.3 million for the same period in 2020. The increase of $2.7 million was primarily due to additional research and development efforts, manufacturing activities, and personnel expenses to support the advancement of our pipeline.

General and administrative expenses were $5.7 million for the second quarter of 2021 as compared to $3.7 million for the same period in 2020. The increase of $2.0 million was primarily due to increase in personnel expenses and other external expenses to support Keros’ organizational growth.

Keros’ cash and cash equivalents as of June 30, 2021 was $237.1 million compared to $265.9 million as of December 31, 2020. Keros expects that the cash and cash equivalents it had on hand at June 30, 2021 will fund its operating expenses and capital expenditure requirements into the fourth quarter of 2023.

About Keros Therapeutics, Inc.

Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematologic and musculoskeletal disorders with high unmet medical need. Keros is a leader in understanding the role of the Transforming Growth Factor-Beta family of proteins, which are master regulators of red blood cell and platelet production as well as of the growth, repair and maintenance of muscle and bone. Keros’ lead protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and in patients with myelofibrosis. Keros’ lead small molecule product candidate, KER-047, is being developed for the treatment of anemia resulting from iron imbalance, as well as for the treatment of fibrodysplasia ossificans progressiva. Keros’ third product candidate, KER-012, is being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension.

Cautionary Note Regarding Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “anticipates,” “believes,” “expects,” “intends,” “plans,” “potential,” “projects,” “would” and “future” or similar expressions are intended to identify forward-looking statements. Examples of these forward-looking statements include statements concerning: Keros’ expectations regarding its growth, strategy, progress and timing of its preclinical studies and clinical trials for KER-050, KER-047 and KER-012; the potential impact of COVID-19 on Keros’ ongoing and planned preclinical studies, clinical trials, business and operations; and Keros’ expected cash runway. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: Keros’ limited operating history and historical losses; Keros’ ability to raise additional funding to complete the development and any commercialization of its product candidates; Keros’ dependence on the success of its lead product candidates, KER-050 and KER-047; that Keros may be delayed in initiating, enrolling or completing any clinical trials; competition from third parties that are developing products for similar uses; Keros’ ability to obtain, maintain and protect its intellectual property; Keros’ dependence on third parties in connection with manufacturing, clinical trials and preclinical studies; and risks relating to the impact on Keros’ business of the COVID-19 pandemic or similar public health crises.

These and other risks are described more fully in Keros’ filings with the Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of the Company’s Quarterly Report on Form 10-Q, filed with the SEC on May 6, 2021, and its other documents subsequently filed with or furnished to the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, Keros undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Investor Contact:

Mike Biega
[email protected]
617-921-966



KEROS THERAPEUTICS, INC.

Condensed Consolidated Statements of Operations

(In thousands, except share and per share data)
(Unaudited)

  THREE MONTHS ENDED
JUNE 30,
  SIX MONTHS ENDED
JUNE 30,
2021   2020   2021   2020
REVENUE:              
License revenue $ 100       $       $ 100       $    
Total revenue 100             100          
OPERATING EXPENSES:              
Research and development (9,983 )     (7,264 )     (21,478 )     (15,791 )  
General and administrative (5,658 )     (3,650 )     (9,932 )     (5,627 )  
Total operating expenses (15,641 )     (10,914 )     (31,410 )     (21,418 )  
LOSS FROM OPERATIONS (15,541 )     (10,914 )     (31,310 )     (21,418 )  
OTHER INCOME (EXPENSE), NET              
Interest expense, net (1 )     (1 )     (2 )     (3 )  
Change in fair value of preferred stock tranche obligation                   (1,490 )  
Other income (expense), net (80 )     158       (145 )     90    
Total other income (expense), net (81 )     157       (147 )     (1,403 )  
Loss before income taxes (15,622 )     (10,757 )     (31,457 )     (22,821 )  
Income tax (provision) benefit             (50 )     172    
Net loss $ (15,622 )     $ (10,757 )     $ (31,507 )     $ (22,649 )  
Net loss attributable to common stockholders—basic and diluted $ (15,622 )     $ (10,963 )     $ (31,507 )     $ (23,661 )  
Net loss per share attributable to common stockholders—basic and diluted $ (0.67 )     $ (0.62 )     $ (1.35 )     $ (2.35 )  
Weighted-average common stock outstanding—basic and diluted 23,305,673       17,623,994       23,267,943       10,054,026    
                               

KEROS THERAPEUTICS, INC.

Condensed Consolidated Balance Sheets

(In thousands, except share and per share data)
(Unaudited)

  JUNE 30,

2021
  DECEMBER 31,

2020
ASSETS      
CURRENT ASSETS:      
Cash and cash equivalents 237,113       265,876    
Accounts receivable 100          
Prepaid expenses and other current assets 4,204       1,850    
Total current assets 241,417       267,726    
Operating lease right-of-use assets 676       878    
Property and equipment, net 1,253       724    
Restricted cash 115       115    
TOTAL ASSETS 243,461       269,443    
LIABILITIES AND STOCKHOLDERS’ EQUITY      
CURRENT LIABILITIES:      
Accounts payable 1,372       2,149    
Current portion of operating lease liabilities 449       423    
Accrued expenses and other current liabilities 5,710       4,612    
Total current liabilities 7,531       7,184    
Operating lease liabilities, net of current portion 242       476    
Other liabilities 32       62    
Total liabilities 7,805       7,722    
STOCKHOLDERS’ EQUITY:      
Common stock, par value of $0.0001 per share; 200,000,000 authorized as of June 30, 2021 and December 31, 2020, respectively; 23,328,771 and 23,192,866 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively 2       2    
Additional paid-in capital 332,172       326,730    
Accumulated deficit (96,518 )     (65,011 )  
Total stockholders’ equity 235,656       261,721    
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY 243,461       269,443    



WillScot Mobile Mini Holdings Announces Second Quarter Results and Updates 2021 Outlook

Leasing Operations Accelerate Across All Segments, Successful ERP Cutover Completed, Over $216 Million Returned to Shareholders Year-To-Date, Investor Day Announced In November

PHOENIX, Aug. 05, 2021 (GLOBE NEWSWIRE) — WillScot Mobile Mini Holdings Corp. (“WillScot Mobile Mini Holdings” or the “Company”) (Nasdaq: WSC), the North American leader in innovative flexible work space and portable storage solutions, today announced second quarter 2021 results and provided an update on operations, the current market environment, and merger integration activities.

The Company will host an investor day in New York on November 8, 2021. Further details will be provided at a later date.

On July 1, 2020, Williams Scotsman, Inc. closed the merger with Mobile Mini, Inc. (the “Merger”) and assumed the name WillScot Mobile Mini Holdings Corp. (Nasdaq: WSC). Our reported results only include Mobile Mini for the periods subsequent to the Merger. Our Pro Forma Results include Mobile Mini’s results as if the Merger and financing transactions had occurred on January 1, 2019, which we believe is a better representation of how the combined company has performed over time. Following the Merger, we expanded our reporting segments from two segments to four reporting segments. The North America Modular segment aligns with the WillScot legacy business prior to the Merger and the North America Storage, UK Storage and Tank and Pump segments align with the Mobile Mini segments prior to the Merger.

WillScot Mobile Mini Holdings’ Financial Highlights

1


Highlights of Second Quarter Results

  • Total revenues of $461.1 million increased by $204.2 million relative to prior year, or 79.5%, driven by the addition of Mobile Mini’s revenues to our consolidated results, upon closing of the Merger on July 1, 2020, as well as due to increased core leasing revenues in the NA Modular segment.
    • Modular space monthly rental rates in the NA Modular segment increased by 19.7% year over year while delivery volumes increased 12.0% year over year.
  • Adjusted EBITDA of $175.5 million increased by $78.0 million, or 80.0% year over year, driven both by the addition of Mobile Mini to our results and 6.2% year over year organic growth in the NA Modular segment.
  • Adjusted EBITDA Margin of 38.1% increased by 10 basis points (“bps”) relative to prior year, driven by the addition of Mobile Mini’s higher margin portable storage business, and partly offset by accelerating activations and associated variable costs and delivery and installation revenues in the quarter.
  • Net income of $20.4 million increased by $34.5 million year over year and included $15.0 million of integration and restructuring charges, an $8.0 million non-cash tax expense due to a statutory rate increase in the UK, a $2.8 million non-cash loss on debt extinguishment, and a $0.6 million fair value gain on warrant liabilities. Net Income Excluding Gain/Loss from Warrants of $19.8 million increased by $7.0 million year over year.
  • Generated $82.1 million of free cash flow, an increase of $43.1 million or 110% relative to prior year, and representing a free cash flow margin of 18%.
  • Maintained leverage at 3.7x our pro forma last-twelve-months Adjusted EBITDA of $682.3 million while repurchasing $132.7 million of common stock and warrants.
  • Redeemed $58.5 million of our 6.125% senior notes due 2025, using capacity available in our lower cost ABL facility.

Highlights of Second Quarter Pro Forma Results

  • Pro Forma total revenues increased 18.1% or $70.6 million relative to prior year, driven by increases in leasing revenue and delivery and installation revenue.
  • Leasing revenues of $343.2 million increased by 18.2% year over year due to continued increases in pricing and value-added products and stabilization of unit on rent volumes.
    • In NA Modular, modular space unit monthly rental rates increased by 19.7%. In NA Storage, portable storage unit and modular space unit monthly rental rates increased by 10.3%. In UK Storage, modular space monthly rental rates increased 39.9%.
    • Modular space unit deliveries in NA Modular increased by 12%.
    • Portable storage and modular space unit deliveries in NA Storage increased 42%, which is in line with 2019 delivery levels.
  • Adjusted EBITDA of $175.5 million, increased by $21.7 million, or 14.1%, year over year on a pro forma basis, with strong growth across all segments.
  • Adjusted EBITDA Margin of 38.1% decreased by 130 bps relative to prior year on a pro forma basis as expected due to increased activity levels. Accelerating deliveries created incremental variable costs and increased delivery and installation revenues, which are lower margin revenues compared to total revenues.

Refer to the Supplemental Pro Forma Financial Information section on Form 10-Q to be filed with the SEC and made available on the WillScot Mobile Mini Holdings Corp. investor relations website for full reconciliations of our reported and pro forma results.

  Three Months Ended June 30,   Six Months Ended June 30,

(in thousands)
2021   2020   2021   2020
Revenue $ 461,102     $ 256,862       $ 886,425     $ 512,683  
Consolidated net income (loss) $ 20,371     $ (14,130 )     $ 24,818     $ 77,525  
Adjusted EBITDA1 $ 175,495     $ 97,520       $ 339,080     $ 187,062  
Net cash provided by operating activities $ 139,537     $ 75,379       $ 261,608     $ 113,727  
Free Cash Flow1 $ 82,056     $ 38,996       $ 173,216     $ 46,804  

  Three Months Ended June 30,   Six Months Ended June 30,

Pro Forma Adjusted EBITDA



1



by Segment (in thousands)
2021   2020   2021   2020
NA Modular $ 103,545     $ 97,520     $ 200,916     $ 187,064  
NA Storage 49,526     40,770     95,848     84,764  
UK Storage 12,328     6,853     23,392     13,258  
Tank and Pump 10,096     8,659     18,924     18,136  
Consolidated Adjusted EBITDA $ 175,495     $ 153,802     $ 339,080     $ 303,222  

Management Commentary

1

Brad Soultz, Chief Executive Officer of WillScot Mobile Mini Holdings, commented “our second quarter results were excellent. Our team proved once again that we can deliver operationally while executing a complex integration with precision. And our diversified portfolio is positioned for growth through a powerful combination of internal initiatives and end market strength. In our NA Modular segment, units on rent stabilized sequentially, as deliveries across our end markets ramped. Historical pricing trends accelerated at a record pace, with a 19.7% year over year increase in average monthly rental rate, underpinned by increases in core pricing and VAPS penetration and augmented by the return of shorter duration special events as COVID restrictions relaxed relative to last year. Our NA Storage segment demonstrated impressive rate improvement, with a 10.3% year over year price increase as we focused on rates on new activations of storage units and continued core pricing increases on the ground level office fleet. Our UK Storage segment booked another tremendous quarter, with blended rates up 26.4%, units on rent up 13.5%, and Adjusted EBITDA up nearly 80% year over year. Finally, our Tank & Pump segment increased its OEC utilization to 71.2% and inflected strongly, generating year over year Revenue and EBITDA growth in the quarter as end markets recovered.”

Soultz continued, “While these results are outstanding, I’m most proud of the relentless focus demonstrated by our team as we migrated the legacy WillScot business onto Mobile Mini’s SAP platform. This work was painstaking and all-consuming for many on our team, yet we executed flawlessly while minimizing disruptions in the business. This ERP cutover established a foundation from which we will build and, on the one-year anniversary of the WillScot and Mobile Mini merger, is the catalyst which will allow us to begin executing our strategy as a combined company.”

Tim Boswell, Chief Financial Officer of WillScot Mobile Mini Holdings, commented “in the second quarter, we saw improvement across virtually every financial and operational metric in our business. Cash generation remains robust, with $82.1 million in free cash flow in the quarter and a 20% free cash flow margin in the twelve months since the merger closed, despite cash costs from our integration efforts over that period and the fact that we are only just beginning to realize synergies from the Mobile Mini merger. With the SAP migration complete, synergy realization will accelerate as our teams restore their focus on the portfolio of commercial and operational value creation levers that we have identified. Our outlook for the remainder of 2021 and our run-rate expectations for 2022 continue to improve as reflected in our updated financial guidance. All of these factors together gave us confidence to put our balance sheet to work in the quarter, maintaining leverage at 3.7x, repurchasing $135 million of common stock and warrants, and redeeming $58.5 million of our senior notes due 2025. With the most difficult phase of the integration behind us, we are squarely focused on the future and unlocking the value in this platform, and we look forward to discussing these opportunities at our Investor Day on November 8th in New York.”

Second Quarter 2021 Results

1

Total revenues increased 79.5% to $461.1 million, while leasing revenues increased 80.5% versus the prior year quarter driven primarily by the addition of Mobile Mini’s revenues to our consolidated results as well as due to increased leasing revenues in the NA Modular segment.

  • Average modular space units on rent increased 23,372 units, or 26.8%, and average portable storage units on rent increased 135,867 units, both driven by the Mobile Mini Merger.
  • Average modular space monthly rental rate increased $67, or 10.0% to $736 driven by a $132, or 19.7% increase in the NA Modular segment, offset by the dilutive impact of lower rates due to mix on the Mobile Mini modular space units.
  • Average portable storage monthly rental rate increased $19, or 15.8% to $139 driven by the accretive impact of higher rates from the Mobile Mini portable storage fleet.
  • NA Modular segment revenue increased $32.5 million, or 12.7%, to $289.4 million, primarily driven by a $27.5 million, or 14.5%. increase to our core leasing revenue due to continued growth of pricing and value added products:
    • NA Modular space average monthly rental rate of $801 increased 19.7% year over year, representing a continuation of the long-term price optimization and VAPS penetration opportunities across our portfolio.
    • Average modular space units on rent decreased 2,342, or 2.7% year over year driven by lower deliveries, during 2020 as a result of the COVID-19 pandemic. Sequentially from March 31, 2021, average modular space units on rent were flat.

Adjusted EBITDA of $175.5 million increased $78.0 million, or 80.0% year over year. Of this increase, $71.9 million was driven by the addition of Mobile Mini to our consolidated results, with the remainder driven by strong organic growth in the NA Modular segment.

  • Adjusted EBITDA in our NA Modular segment increased $6.0 million, or 6.2% to $103.5 million primarily driven by a $9.1 million, or 6.0%, increase in leasing and services gross profit excluding depreciation driven by increased pricing and VAPS. These increases more than offset a $14.8 million increase in variable leasing costs, driven by the 12% increase in delivery volumes versus prior year.
  • Consolidated Adjusted EBITDA Margin was 38.1% in the second quarter and increased 10 bps versus prior year, driven by the addition of Mobile Mini’s higher margin portable storage business, offset by a higher proportion of delivery and installation revenues to total revenues and the increased variable costs in the current year quarter.

Net income of $20.4 million for the three months ended June 30, 2021 included a $0.6 million gain on the change in fair value of common stock warrant liabilities. Net Income Excluding Gain/Loss from Warrants of $19.8 million for the three months ended June 30, 2021, represented an increase of $7.0 million, and included a $2.8 million loss on extinguishment of debt related to the partial redemption of the 2025 Secured Notes, a $8.0 million non-cash tax expense due to a statutory rate increase in the UK, and $15.0 million of discrete costs expensed in the period related to transaction and integration activities. Discrete costs in the period included $7.6 million of integration costs and $7.4 million of restructuring costs, lease impairment expense and other related charges.

Free Cash Flow increased by $43.1 million year over year to $82.1 million, representing a 17.8% free cash flow margin.

Second Quarter 2020 Pro Forma Results

1


Total revenues increased 18.1% or $70.6 million on a pro forma basis to $461.1 million driven by an increase in leasing revenues of $52.9 million, or 18.2% year over year.

  • Consolidated average modular space monthly rental rates increased $122, or 19.9% year over year driven by a $132, or 19.7%, increase in the NA Modular segment and a $110, or 23.8% increase in the NA Storage segment, and a $125, or 39.9% increase in the UK Storage segment.
  • Consolidated average portable storage monthly rental rates increased $10, or 7.8% versus prior year.
  • Average modular space units on rent declined 0.3% year over year driven by lower deliveries during 2020 as a result of the COVID-19 pandemic. However, average modular space units on rent improved 0.1% sequentially from Q1 to Q2. Portable storage units on rent increased 8.2% year over year.

Adjusted EBITDA of $175.5 million, represented a $21.7 million, or 14.1%, increase year over year, with strong growth across the NA Modular, NA Storage, UK Storage and Tank and Pump segments.

Adjusted EBITDA margin contracted 130 bps year over year to 38.1% as expected, driven by a higher proportion of delivery and installation revenues to total revenues and a $23.4 million increase in variable costs to support higher activity levels in the current year quarter across all segments.

Capitalization and Liquidity Update

1,3


As of June 30, 2021

  • Generated $82.1 million of free cash flow in the second quarter and a 20% free cash flow margin over the last twelve months.
  • Repurchased 3.9 million shares for $108.2 million in connection with a secondary offering and repurchased an additional $26.5 million of common stock and warrants, returning a total of $134.7 million to our shareholders.
  • Redeemed $58.5 million of our 6.125% senior notes due 2025, refinancing this balance to our lower-cost asset-based revolving credit facility.
  • Over $0.9 billion of excess availability under the asset-based revolving credit facility, a flexible covenant structure, and accelerating free cash flow provide ample liquidity to fund multiple capital allocation alternatives.
  • Weighted average interest rate is approximately 3.8% and annual cash interest expense based on the current debt structure is approximately $98 million.
  • No debt maturities prior to 2025.
  • Maintained leverage at 3.7x our pro forma last-twelve-months Adjusted EBITDA of $682.3 million and are on a rapid deleveraging trajectory.

2021 Outlook

1, 2, 3

This guidance is subject to risks and uncertainties, including those described in “Forward-Looking Statements” below.

  2020 Pro Forma Results   Prior 2021 Outlook   Current 2021 Outlook
Revenue $1,652 million   $1,750 million – $1,830 million   $1,800 million – $1,850 million
Adjusted EBITDA1,2 $646 million   $690 million – $720 million   $710 million – $730 million
Net CAPEX2,3 $161 million   $190 million – $230 million   $200 million – $230 million

1 – Adjusted EBITDA, Adjusted EBITDA Margin, and Free Cash Flow are non-GAAP financial measures. Further information and reconciliations for these Non-GAAP measures to the most directly comparable financial measure under generally accepted accounting principles in the US (“GAAP”) is included at the end of this press release.

2 – Information reconciling forward-looking Adjusted EBITDA and Net CAPEX to GAAP financial measures is unavailable to the Company without unreasonable effort and therefore no reconciliation to the most comparable GAAP measures is provided.

3 – Net CAPEX is a non-GAAP financial measure. Please see the non-GAAP reconciliation tables included at the end of this press release.

Non-GAAP Financial Measures

This press release includes non-GAAP financial measures, including Adjusted EBITDA, Adjusted EBITDA Margin, Free Cash Flow, Free Cash Flow Margin, Pro Forma Revenue, Adjusted Gross Profit, Adjusted Gross Profit Percentage, Net Income Excluding Gain/Loss from Warrants, and Net CAPEX. Adjusted EBITDA is defined as net income (loss) before income tax expense, net interest expense, depreciation and amortization adjusted for non-cash items considered non-core to business operations including net currency gains and losses, goodwill and other impairment charges, restructuring costs, costs to integrate acquired companies, costs incurred related to transactions, non-cash charges for stock compensation plans, gains and losses resulting from changes in fair value and extinguishment of warrant liabilities, and other discrete expenses. Adjusted EBITDA margin is defined as Adjusted EBITDA divided by revenue. Free Cash Flow is defined as net cash provided by operating activities, less purchases of, and proceeds from, rental equipment and property, plant and equipment, which are all included in cash flows from investing activities. Net CAPEX is defined as purchases of rental equipment and refurbishments and purchases of property, plant and equipment (collectively, “Total Capital Expenditures”), less proceeds from sale of rental equipment and proceeds from the sale of property, plant and equipment (collectively, “Total Proceeds”), which are all included in cash flows from investing activities. Free Cash Flow Margin is defined as Free Cash Flow divided by Total Revenue. Our management believes that the presentation of Net CAPEX provides useful information to investors regarding the net capital invested into our rental fleet and plant, property and equipment each year to assist in analyzing the performance of our business. Pro Forma Revenue is defined the same as revenue, but includes pre-acquisition results from Mobile Mini for all periods presented. Adjusted Gross Profit is defined as gross profit plus depreciation on rental equipment. Adjusted Gross Profit Percentage is defined as Adjusted Gross Profit divided by revenue. Net Income Excluding Gain/Loss from Warrants is defined as Net Income plus or minus the impact of the change in the fair value of the warrant liability. The Company believes that our financial statements that will include the impact of this mark-to-market expense or income may not be necessarily reflective of the actual financial performance of our business. The Company believes that Adjusted EBITDA and Adjusted EBITDA margin are useful to investors because they (i) allow investors to compare performance over various reporting periods on a consistent basis by removing from operating results the impact of items that do not reflect core operating performance; (ii) are used by our board of directors and management to assess our performance; (iii) may, subject to the limitations described below, enable investors to compare the performance of the Company to its competitors; and (iv) provide additional tools for investors to use in evaluating ongoing operating results and trends. The Company believes that pro forma revenue is useful to investors because they allow investors to compare performance of the combined Company over various reporting periods on a consistent basis. The Company believes that Net CAPEX provide useful additional information concerning cash flow available to meet future debt service obligations. However, Adjusted EBITDA is not a measure of financial performance or liquidity under GAAP and, accordingly, should not be considered as an alternative to net income or cash flow from operating activities as an indicator of operating performance or liquidity. These non-GAAP measures should not be considered in isolation from, or as an alternative to, financial measures determined in accordance with GAAP. Other companies may calculate Adjusted EBITDA and other non-GAAP financial measures differently, and therefore the Company’s non-GAAP financial measures may not be directly comparable to similarly-titled measures of other companies. For reconciliation of the non-GAAP measures used in this press release (except as explained below), see “Reconciliation of Non-GAAP Financial Measures” included in this press release.

Information reconciling forward-looking Adjusted EBITDA to GAAP financial measures is unavailable to the Company without unreasonable effort. We cannot provide reconciliations of forward-looking Adjusted EBITDA to GAAP financial measures because certain items required for such reconciliations are outside of our control and/or cannot be reasonably predicted, such as the provision for income taxes. Preparation of such reconciliations would require a forward-looking balance sheet, statement of income and statement of cash flow, prepared in accordance with GAAP, and such forward-looking financial statements are unavailable to the Company without unreasonable effort. Although we provide a range of Adjusted EBITDA that we believe will be achieved, we cannot accurately predict all the components of the Adjusted EBITDA calculation. The Company provides Adjusted EBITDA guidance because we believe that Adjusted EBITDA, when viewed with our results under GAAP, provides useful information for the reasons noted above.

Conference Call Information

WillScot Mobile Mini Holdings will host a conference call and webcast to discuss its second quarter 2021 results and outlook at 10 a.m. Eastern Time on Friday, August 6, 2021. The live call may be accessed by dialing (855) 312-9420 (US/Canada toll-free) or (210) 874-7774 (international) and asking to be connected to the WillScot Mobile Mini Holdings call. A live webcast will also be accessible via the “Events & Presentations” section of the Company’s investor relations website www.willscotmobilemini.com. Choose “Events” and select the information pertaining to the WillScot Mobile Mini Holdings Second Quarter 2021 Conference Call. Additionally, there will be slides accompanying the webcast. Please allow at least 15 minutes prior to the call to register, download and install any necessary software. For those unable to listen to the live broadcast, an audio webcast of the call will be available for 60 days on the Company’s investor relations website.

About WillScot Mobile Mini Holdings

WillScot Mobile Mini Holdings trades on the Nasdaq stock exchange under the ticker symbol “WSC.” Headquartered in Phoenix, Arizona, the Company is a leading business services provider specializing in innovative flexible workspace and portable storage solutions. WillScot Mobile Mini services diverse end markets across all sectors of the economy from a network of approximately 270 branch locations and additional drop lots throughout the United States, Canada, Mexico, and the United Kingdom.

Forward-Looking Statements

This press release contains forward-looking statements (including the guidance/outlook contained herein) within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended. The words “estimates,” “expects,” “anticipates,” “believes,” “forecasts,” “plans,” “intends,” “may,” “will,” “should,” “shall,” “outlook” and variations of these words and similar expressions identify forward-looking statements, which are generally not historical in nature. Certain of these forward-looking statements include statements relating to: the acceleration of synergies; our ability to continue to improve results; our future cash flow and liquidity, our deleveraging trajectory, continued VAPS penetration opportunities, and our revenue, Adjusted EBITDA and Net Capex outlooks. Forward-looking statements are subject to a number of risks, uncertainties, assumptions and other important factors, many of which are outside our control, which could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Although the Company believes that these forward-looking statements are based on reasonable assumptions, they are predictions and we can give no assurance that any such forward-looking statement will materialize. Important factors that may affect actual results or outcomes include, among others, our ability to acquire and integrate new assets and operations; our ability to achieve planned synergies related to acquisitions; our ability to manage growth and execute our business plan; our estimates of the size of the markets for our products; the rate and degree of market acceptance of our products; the success of other competing modular space and portable storage solutions that exist or may become available; rising costs adversely affecting our profitability; potential litigation involving our Company; general economic and market conditions impacting demand for our products and services; our ability to maintain an effective system of internal controls; and such other risks and uncertainties described in the periodic reports we file with the SEC from time to time (including our Form 10-K/A for the year ended December 31, 2020), which are available through the SEC’s EDGAR system at www.sec.gov and on our website. Any forward-looking statement speaks only at the date which it is made, and the Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Additional Information and Where to Find It

Additional information can be found on the company’s website at www.willscotmobilemini.com.

Contact Information    
     
Investor Inquiries:   Media Inquiries:
Nick Girardi   Scott Junk
[email protected]   [email protected]
     



WillScot Corporation

Consolidated Statements of Operations

(in thousands, except share and per share data)

  Three Months Ended June 30,   Six Months Ended June 30,

(in thousands, except share and per share data)
2021   2020   2021   2020
Revenues:              
Leasing and services revenue:              
Leasing $ 343,179     $ 190,143     $ 658,841     $ 378,495  
Delivery and installation 91,680     51,640     175,184     102,710  
Sales revenue:              
New units 11,008     9,763     21,963     19,376  
Rental units 15,235     5,316     30,437     12,102  
Total revenues 461,102     256,862     886,425     512,683  
Costs:              
Costs of leasing and services:              
Leasing 83,032     47,747     152,927     97,556  
Delivery and installation 77,153     43,523     147,289     87,388  
Costs of sales:              
New units 7,052     6,331     14,161     12,534  
Rental units 8,162     3,803     17,267     7,609  
Depreciation of rental equipment 62,893     45,494     118,591     91,442  
Gross profit 222,810     109,964     436,190     216,154  
Expenses:              
Selling, general and administrative 122,387     63,653     238,872     129,190  
Transaction costs     1,619     844     11,050  
Other depreciation and amortization 21,622     2,883     39,946     5,957  
Lease impairment expense and other related charges 474     1,394     1,727     3,055  
Restructuring costs 6,960     749     10,102     689  
Currency losses (gains), net 33     (380 )   69     518  
Other expense (income), net 719     (1,021 )   (1,269 )   (745 )
Operating income 70,615     41,067     145,899     66,440  
Interest expense 29,212     28,519     59,176     56,776  
Fair value (gain) loss on common stock warrant liabilities (610 )   26,963     26,597     (68,366 )
Loss on extinguishment of debt 2,814         5,999      
Income (loss) before income tax 39,199     (14,415 )   54,127     78,030  
Income tax expense (benefit) 18,828     (285 )   29,309     505  
Net income (loss) 20,371     (14,130 )   24,818     77,525  
Net income attributable to non-controlling interest, net of tax     1,343         1,213  
Net income (loss) attributable to WillScot Mobile Mini $ 20,371     $ (15,473 )   $ 24,818     $ 76,312  
               
Earnings (loss) per share attributable to WillScot Mobile
Mini common shareholders
             
Basic $ 0.09     $ (0.14 )   $ 0.11     $ 0.69  
Diluted $ 0.08     $ (0.14 )   $ 0.11     $ 0.06  
Weighted average shares:              
Basic 228,406,812     110,692,426     228,350,318     110,174,536  
Diluted 236,536,713     110,692,426     234,898,911     112,336,118  



Unaudited Segment Operating Data

Comparison of Three Months Ended June 30, 2021 and 2020

  Three Months Ended June 30, 2021

(in thousands, except for units on rent and rates)
NA Modular   NA Storage   UK Storage   Tank and
Pump
  Total
Revenue $ 289,382     $ 115,794     $ 28,432     $ 27,494     $ 461,102  
Gross profit $ 116,136     $ 75,721     $ 17,937     $ 13,016     $ 222,810  
Adjusted EBITDA $ 103,545     $ 49,526     $ 12,328     $ 10,096     $ 175,495  
Capital expenditures for rental equipment $ 49,364     $ 8,773     $ 4,226     $ 2,919     $ 65,282  
Average modular space units on rent 84,754     16,360     9,354         110,468  
Average modular space utilization rate 67.7 %   78.4 %   84.3 %   %   70.3 %
Average modular space monthly rental rate $ 801     $ 573     $ 438     $     $ 736  
Average portable storage units on rent 13,301     112,862     25,573         151,736  
Average portable storage utilization rate 69.8 %   76.1 %   91.8 %   %   77.7 %
Average portable storage monthly rental rate $ 133     $ 151     $ 88     $     $ 139  
Average tank and pump solutions rental fleet
utilization based on original equipment cost
%   %   %   71.2 %   71.2 %

  Three Months Ended June 30, 2020

(in thousands, except for units on rent and rates)
NA Modular   NA Storage   UK Storage   Tank and
Pump
  Total
Revenue $ 256,862     $     $     $     $ 256,862  
Gross profit $ 109,964     $     $     $     $ 109,964  
Adjusted EBITDA $ 97,520     $     $     $     $ 97,520  
Capital expenditures for rental equipment $ 40,034     $     $     $     $ 40,034  
Average modular space units on rent 87,096                 87,096  
Average modular space utilization rate 68.5 %   %   %   %   68.5 %
Average modular space monthly rental rate $ 669     $     $     $     $ 669  
Average portable storage units on rent 15,869                 15,869  
Average portable storage utilization rate 62.5 %   %   %   %   62.5 %
Average portable storage monthly rental rate $ 120     $     $     $     $ 120  
Average tank and pump solutions rental fleet
utilization based on original equipment cost
%   %   %   %   %



Comparison of the Six Months Ended June 30, 2021 and 2020

  Six Months Ended June 30, 2021

(in thousands, except for units on rent and rates)
NA Modular   NA Storage   UK Storage   Tank and
Pump
  Total
Revenue $ 555,606     $ 223,542     $ 55,439     $ 51,838     $ 886,425  
Gross profit $ 229,138     $ 148,340     $ 34,430     $ 24,282     $ 436,190  
Adjusted EBITDA $ 200,916     $ 95,848     $ 23,392     $ 18,924     $ 339,080  
Capital expenditures for rental equipment $ 88,499     $ 12,245     $ 10,996     $ 6,077     $ 117,817  
Average modular space units on rent 84,737     16,399     9,235         110,371  
Average modular space utilization rate 67.6 %   78.9 %   84.1 %   %   70.3 %
Average modular space monthly rental rate $ 769     $ 554     $ 420     $     $ 703  
Average portable storage units on rent 14,186     109,355     25,112         148,653  
Average portable storage utilization rate 64.8 %   75.0 %   90.5 %   %   76.1 %
Average portable storage monthly rental rate $ 128     $ 150     $ 85     $     $ 137  
Average tank and pump solutions rental fleet
utilization based on original equipment cost
%   %   %   69.3 %   69.3 %

  Six Months Ended June 30, 2020

(in thousands, except for units on rent and rates)
NA Modular   NA Storage   UK Storage   Tank and
Pump
  Total
Revenue $ 512,683     $     $     $     $ 512,683  
Gross profit $ 216,154     $     $     $     $ 216,154  
Adjusted EBITDA $ 187,062     $     $     $     $ 187,062  
Capital expenditures for rental equipment $ 79,682     $     $     $     $ 79,682  
Average modular space units on rent 87,542                 87,542  
Average modular space utilization rate 68.9 %   %   %   %   68.9 %
Average modular space monthly rental rate $ 661     $     $     $     $ 661  
Average portable storage units on rent 16,114                 16,114  
Average portable storage utilization rate 63.5 %   %   %   %   63.5 %
Average portable storage monthly rental rate $ 120     $     $     $     $ 120  
Average tank and pump solutions rental fleet
utilization based on original equipment cost
%   %   %   %   %

  

WillScot Corporation

Consolidated Balance Sheets

(in thousands, except share and per share data)


(in thousands, except share data)
June 30, 2021

(unaudited)
  December 31, 2020  
Assets          
Cash and cash equivalents $ 15,402     $ 24,937  
Trade receivables, net of allowances for credit losses at June 30,
2021 and December 31, 2020 of $36,785 and $29,258,
respectively
365,164     330,942  
Inventories 32,294     23,731  
Prepaid expenses and other current assets 26,686     29,954  
Assets held for sale     12,004  
Total current assets 439,546     421,568  
Rental equipment, net 2,914,572     2,931,646  
Property, plant and equipment, net 303,488     303,650  
Operating lease assets 235,258     232,094  
Goodwill 1,180,737     1,171,219  
Intangible assets, net 474,327     495,947  
Other non-current assets 11,785     16,081  
Total long-term assets 5,120,167     5,150,637  
Total assets $ 5,559,713     $ 5,572,205  
Liabilities and equity      
Accounts payable $ 132,031     $ 106,926  
Accrued expenses 149,670     141,672  
Deferred revenue and customer deposits 151,819     135,485  
Operating lease liabilities – current 49,606     48,063  
Current portion of long-term debt 16,557     16,521  
Total current liabilities 499,683     448,667  
Long-term debt 2,506,295     2,453,809  
Deferred tax liabilities 332,492     307,541  
Operating lease liabilities – non-current 184,874     183,761  
Common stock warrant liabilities     77,404  
Other non-current liabilities 30,956     37,150  
Long-term liabilities 3,054,617     3,059,665  
Total liabilities 3,554,300     3,508,332  
Commitments and contingencies (see Note 17)      
Preferred Stock: $0.0001 par, 1,000,000 shares authorized
and zero shares issued and outstanding at June 30, 2021 and
December 31, 2020
     
Common Stock: $0.0001 par, 500,000,000 shares authorized and
226,832,627 and 229,038,158 shares issued and outstanding at
June 30, 2021 and December 31, 2020, respectively
23     23  
Additional paid-in-capital 3,756,563     3,852,291  
Accumulated other comprehensive loss (24,757 )   (37,207 )
Accumulated deficit (1,726,416 )   (1,751,234 )
Total shareholders’ equity 2,005,413     2,063,873  
Total liabilities and equity $ 5,559,713     $ 5,572,205  



Reconciliation of Non-GAAP Financial Measures

We use certain non-GAAP financial information that we believe is important for purposes of comparison to prior periods and development of future projections and earnings growth prospects. This information is also used by management to measure the profitability of our ongoing operations and analyze our business performance and trends.

We evaluate business segment performance on Adjusted EBITDA, a non-GAAP measure that excludes certain items as described in the reconciliation of our consolidated net income (loss) to Adjusted EBITDA reconciliation below. We believe that evaluating segment performance excluding such items is meaningful because it provides insight with respect to intrinsic operating results of the Company.

We also regularly evaluate gross profit by segment to assist in the assessment of the operational performance of each operating segment. We consider Adjusted EBITDA to be the more important metric because it more fully captures the business performance of the segments, inclusive of indirect costs.

We also evaluate Free Cash Flow, a non-GAAP measure that provides useful information concerning cash flow available to meet future debt service obligations and working capital requirements.

Adjusted EBITDA

We define EBITDA as net income (loss) plus interest (income) expense, income tax expense (benefit), depreciation and amortization. Our adjusted EBITDA (“Adjusted EBITDA”) reflects the following further adjustments to EBITDA to exclude certain non-cash items and the effect of what we consider transactions or events not related to our core business operations:

  • Currency (gains) losses, net: on monetary assets and liabilities denominated in foreign currencies other than the subsidiaries’ functional currency. Substantially all such currency gains (losses) are unrealized and attributable to financings due to and from affiliated companies.
  • Goodwill and other impairment charges related to non-cash costs associated with impairment charges to goodwill, other intangibles, rental fleet and property, plant and equipment.
  • Restructuring costs, lease impairment expense, and other related charges associated with restructuring plans designed to streamline operations and reduce costs including employee and lease termination costs.
  • Transaction costs including legal and professional fees and other transaction specific related costs.
  • Costs to integrate acquired companies, including outside professional fees, non-capitalized costs associated with system integrations, non-lease branch and fleet relocation expenses, employee training costs, and other costs required to realize cost or revenue synergies.
  • Non-cash charges for stock compensation plans.
  • Other expense includes consulting expenses related to certain one-time projects, financing costs not classified as interest expense, and gains and losses on disposals of property, plant, and equipment.

Adjusted EBITDA has limitations as an analytical tool, and you should not consider the measure in isolation or as a substitute for net income (loss), cash flow from operations or other methods of analyzing the Company’s results as reported under US GAAP. Some of these limitations are:

  • Adjusted EBITDA does not reflect changes in, or cash requirements for our working capital needs;
  • Adjusted EBITDA does not reflect our interest expense, or the cash requirements necessary to service interest or principal payments, on our indebtedness;
  • Adjusted EBITDA does not reflect our tax expense or the cash requirements to pay our taxes;
  • Adjusted EBITDA does not reflect historical cash expenditures or future requirements for capital expenditures or contractual commitments;
  • Adjusted EBITDA does not reflect the impact on earnings or changes resulting from matters that we consider not to be indicative of our future operations;
  • although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future and Adjusted EBITDA does not reflect any cash requirements for such replacements; and
  • other companies in our industry may calculate Adjusted EBITDA differently, limiting its usefulness as a comparative measure.

Because of these limitations, Adjusted EBITDA should not be considered as discretionary cash available to reinvest in the growth of our business or as measures of cash that will be available to meet our obligations. The following tables provide unaudited reconciliations of Net income (loss) to Adjusted EBITDA.



Adjusted EBITDA

  Three Months Ended June 30,   Six Months Ended June 30,

(in thousands)
2021   2020   2021   2020
Net income (loss) $ 20,371     $ (14,130 )   $ 24,818     $ 77,525  
Income tax expense (benefit) 18,828     (285 )   29,309     505  
Loss on extinguishment of debt 2,814         5,999      
Interest expense 29,212     28,519     59,176     56,776  
Depreciation and amortization 84,515     48,377     158,537     97,399  
Fair value loss (gain) on common
stock warrant liabilities
(610 )   26,963     26,597     (68,366 )
Currency losses (gains), net 33     (380 )   69     518  
Restructuring costs, lease impairment
expense and other related charges
7,434     2,143     11,829     3,744  
Transaction costs     1,619     844     11,050  
Integration costs 7,622     2,153     14,964     3,839  
Stock compensation expense 4,707     2,227     8,221     4,014  
Other 569     314     (1,283 )   58  
Adjusted EBITDA $ 175,495     $ 97,520     $ 339,080     $ 187,062  



Net Income Excluding Gain/Loss from Warrants

We define Net Income Excluding Gain/Loss from Warrants as Net Income plus or minus the impact of the change in the fair value of the common stock warrant liability. Management believes that our financial statements that will include the impact of this mark-to-market expense or income may not be necessarily reflective of the actual financial performance of our business.

The following tables provide unaudited reconciliations of Net income (loss) to Net Income Excluding Gain/Loss from Warrants.

  Three Months Ended June 30, Six Months Ended June 30,

(in thousands)
2021   2020 2021   2020
Net income (loss) $ 20,371     $ (14,130 ) $ 24,818     $ 77,525  
Fair value (gain) loss on common stock warrant liabilities (610 )   26,963   26,597     (68,366 )
Net Income (Loss) Excluding Gain/Loss from Warrants $ 19,761     $ 12,833   $ 51,415     $ 9,159  

Adjusted EBITDA Margin Non-GAAP Reconciliation

We define Adjusted EBITDA Margin as Adjusted EBITDA divided by Revenue. Management believes that the presentation of Adjusted EBITDA Margin provides useful information to investors regarding the performance of our business.

The following tables provide unaudited reconciliations of Adjusted EBITDA Margin.

  Three Months Ended June 30,   Six Months Ended June 30,

(in thousands)
2021   2020   2021   2020
Adjusted EBITDA (A) $ 175,495     $ 97,520     $ 339,080     $ 187,062  
Revenue (B) $ 461,102     $ 256,862     $ 886,425     $ 512,683  
Adjusted EBITDA Margin (A/B) 38.1 %   38.0 %   38.3 %   36.5 %



Free Cash Flow and Free Cash Flow Margin

We define Free Cash Flow as net cash provided by operating activities, less purchases of, and proceeds from, rental equipment and property, plant and equipment, which are all included in cash flows from investing activities. Free Cash Flow Margin is defined as Free Cash Flow divided by Total Revenue. Management believes that the presentation of Free Cash Flow and Free Cash Flow Margin provide useful information to investors regarding our results of operations because they provide useful additional information concerning cash flow available to meet future debt service obligations and working capital requirements.

The following table provides unaudited reconciliations of net cash provided by operating activities to Free Cash Flow.

  Three Months Ended June 30,   Six Months Ended June 30,

(in thousands)
2021   2020   2021   2020
Net cash provided by operating activities $ 139,537       $ 75,379       $ 261,608       $ 113,727    
Purchase of rental equipment and refurbishments (65,282 )     (40,034 )     (117,817 )     (79,682 )  
Proceeds from sale of rental equipment 15,235       5,316       30,437       12,102    
Purchase of property, plant and equipment (10,143 )     (1,668 )     (17,450 )     (3,186 )  
Proceeds from the sale of property, plant and equipment 2,709       3       16,438       3,843    
Free Cash Flow (A) $ 82,056       $ 38,996       $ 173,216       $ 46,804    
               
Revenue (B) $ 461,102       $ 256,862       $ 886,425       $ 512,683    
Free Cash Flow Margin (A/B) 17.8   %   15.2   %   19.5   %   9.1   %



Adjusted Gross Profit and Adjusted Gross Profit Percentage

We define Adjusted Gross Profit as gross profit plus depreciation on rental equipment. Adjusted Gross Profit Percentage is defined as Adjusted Gross Profit divided by revenue. Adjusted Gross Profit and Percentage are not measurements of our financial performance under GAAP and should not be considered as an alternative to gross profit, gross profit percentage, or other performance measures derived in accordance with GAAP. In addition, our measurement of Adjusted Gross Profit and Adjusted Gross Profit Percentage may not be comparable to similarly titled measures of other companies. Our management believes that the presentation of Adjusted Gross Profit and Adjusted Gross Profit Percentage provides useful information to investors regarding our results of operations because it assists in analyzing the performance of our business.

The following table provides unaudited reconciliations of gross profit to Adjusted Gross Profit and Adjusted Gross Profit Percentage.

  Three Months Ended   Six Months Ended
  June 30,   June 30,

(in thousands)
2021   2020   2021   2021
Revenue (A) $ 461,102     $ 256,862     $ 886,425     $ 512,683  
               
Gross profit (B) $ 222,810     $ 109,964     $ 436,190     $ 216,154  
Depreciation of rental equipment 62,893     45,494     118,591     91,442  
Adjusted Gross Profit (C) $ 285,703     $ 155,458     $ 554,781     $ 307,596  
               
Gross Profit Percentage (B/A) 48.3 %   42.8 %   49.2 %   42.2 %
Adjusted Gross Profit Percentage (C/A) 62.0 %   60.5 %   62.6 %   60.0 %

Net CAPEX

We define Net CAPEX as purchases of rental equipment and refurbishments and purchases of property, plant and equipment (collectively, “Total Capital Expenditures”), less proceeds from sale of rental equipment and proceeds from the sale of property, plant and equipment (collectively, “Total Proceeds”), which are all included in cash flows from investing activities. Our management believes that the presentation of Net CAPEX provides useful information to investors regarding the net capital invested into our rental fleet and plant, property and equipment each year to assist in analyzing the performance of our business.

The following table provides unaudited reconciliations of Net CAPEX:

  Three Months Ended   Six Months Ended
  June 30,   June 30,

(in thousands)
2021   2020   2021   2020
Total purchases of rental equipment and refurbishments $ (65,282 )   $ (40,034 )   $ (117,817 )   $ (79,682 )
Total proceeds from sale of rental equipment 15,235     5,316     30,437     12,102  
Net CAPEX for Rental Equipment (50,047 )   (34,718 )   (87,380 )   (67,580 )
Purchase of property, plant and equipment (10,143 )   (1,668 )   (17,450 )   (3,186 )
Proceeds from sale of property, plant and equipment 2,709     3     16,438     3,843  
Net CAPEX $ (57,481 )   $ (36,383 )   $ (88,392 )   $ (66,923 )



Opiant Pharmaceuticals Announces Second Quarter 2021 Financial Results and Provides Corporate Update

SANTA MONICA, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three and six months ended June 30, 2021, and provided a corporate update. Recent highlights include:

Pipeline and Corporate Update:


OPNT003, nasal nalmefene, for opioid overdose

:

  • Completed confirmatory pharmacokinetic (“PK”) study; data demonstrate rapid absorption and higher plasma concentrations versus a nalmefene intramuscular injection (p<0.0001)
  • Data from Pharmacodynamic (“PD”) anticipated later in the fourth quarter
  • Increasing need for OPNT003, with the Center for Disease Control released provisional overdose death data (predicted) for the full year 2020:

    • 69,710 overdoses were caused by opioids, up 30% vs 2019, the highest annual increase in three decades
    • 57,550 opioid overdose deaths, or approximately 82%, were due to illicit synthetic opioids, including fentanyl


OPNT004, drinabant, for Acute Cannabinoid Overdose

: Preclinical activities and formulation development on track to support a Phase 1 study with parenteral drinabant in 2022


OPNT002, nasal naltrexone, for Alcohol Use Disorder

: Start of Phase 2 study remains on pause; Company continues to assess optimal time to proceed


Appointed Matthew Ruth as Chief Commercial Officer on July 12

; Mr. Ruth led the launch and commercialization of the first FDA-approved nasal naloxone spray to treat opioid overdose


Appointed Brian Gorman to Executive Vice President, Corporate Development and General Counsel

;
Mr. Gorman was promoted from General Counsel

Financial Highlights


Q2 revenues of $11.3 million

, a 79% increase over the same period in 2020, 
driven by NARCAN® Nasal Spray (“NARCAN®”) royalties


$48.5 million

in cash, cash equivalents and marketable securities (as of June 30, 2021)


Raises full-year 2021 royalty revenue guidance

from the sale of NARCAN® Nasal Spray to approximately $28.9 million and

raises full year 2021 cash, cash equivalents and marketable securities guidance

in the range of approximately $42 million to $44 million excluding any additional tranches from the convertible debt deal

Commenting, Roger Crystal, M.D., President and Chief Executive Officer of Opiant, said:

“We continue to achieve significant pipeline progress, having recently announced positive confirmatory PK data for OPNT003, nasal nalmefene, which we believe provides strong support for its continued development as a potential new standard of care in the treatment of opioid overdose. We are now focused on the PD study and our preparations for NDA submission, expected to occur at year end or in the first quarter of 2022. This program has never been more relevant as opioid overdose deaths increase. The U.S. experienced its deadliest year in 2020 driven by potent synthetic opioids such as fentanyl. Our goal is to provide the first responders, healthcare providers and communities responding to these highly potent, yet treatable, overdoses with a much needed new rescue agent option as quickly as possible.”

“With the addition of Matt and our promotion of Brian, we are fortunate to have such experienced leaders to support us in delivering on the promise of our pipeline and advancing our mission to create best-in-class medicines for the treatment of addictions and drug overdose.” 

David O’Toole, Chief Financial Officer of Opiant, said:

“Increased demand for NARCAN® in the current quarter meant we recognized significantly higher than expected royalties this quarter. Looking forward through the end of the year, we remain confident in our ability to achieve or even exceed our updated royalty revenue guidance and ending cash target in 2021, while we continue to focus on delivering a potentially breakthrough new treatment to confront the escalating opioid overdose crisis.”

Financial Results for the Three Months Ended June 30, 2021

For the three months ended June 30, 2021, Opiant recorded approximately $11.3 million in revenue, compared to approximately $6.3 million during the corresponding period of 2020. For the three months ended June 30, 2021, the Company recorded approximately $9.3 million of revenue from its license agreement with Emergent BioSolutions, Inc. (“EBS”) for the sale of NARCAN®, compared to approximately $6.3 million in the same period of 2020. Second quarter 2021 sales of NARCAN® were approximately $106.2 million, as reported by EBS. For the three months ended June 30, 2021, the Company recorded approximately $1.9 million in grant and contract revenue compared to approximately $0.1 million in the same period in 2020. The $3.0 million increase in revenue from our license agreement with EBS was primarily due to a $33.4 million increase in net NARCAN® sales in the three months ended June 30, 2021, compared to the three months ended June 30, 2020. The $1.8 million increase in grant and contract revenue was due to the increased funding received from the National Institute of Drug Abuse (“NIDA”) and Biomedical Advanced Research and Development Authority (“BARDA”) for the development of OPNT003.

For the three months ended June 30, 2021, general and administrative (“G&A”) expenses were approximately $2.7 million, as compared to approximately $2.8 million in the comparable period in 2020.

Research and development (“R&D”) expenses for the three months ended June 30, 2021, were approximately $3.2 million, as compared to approximately $0.6 million in the comparable period in 2020. External development expense increased by $2.6 million due to increased activity on the Company’s lead product candidate, OPNT003, nasal nalmefene.

Sales and marketing (“S&M”) expenses for the three months ended June 30, 2021, were approximately $1.0 million for pre-commercialization efforts related to OPNT003, nasal nalmefene. Sales and marketing expense during the three months ended June 30, 2020, were approximately $1.7 million.

Royalty expense for the three months ended June 30, 2021, was approximately $2.1 million and $1.4 million for the comparable period of 2020. The $0.7 million increase was due to increased royalty revenue from net sales of NARCAN®.

Net income for the three months ended June 30, 2021, was approximately $1.7 million, or income of $0.39 per basic share and $0.31 diluted share, compared to net loss of approximately $0.2 million, or a loss of $0.05 per basic and diluted share, for the comparable period of 2020.

Financial Results for the Six Months Ended June 30, 2021

For the six months ended June 30, 2021, Opiant recorded approximately $17.6 million in revenue, compared to approximately $10.6 million during the corresponding period of 2020. For the six months ended June 30, 2021, the Company recorded approximately $13.6 million of revenue from the sale of NARCAN®, compared to approximately $10.5 million in the same period of 2020. First half 2021 sales of NARCAN® were approximately $180.4 million, as reported by EBS. For the six months ended June 30, 2021, the Company recorded approximately $4.0 million in grant and contract revenue compared to approximately $0.1 million in the same period in 2020. The $3.1 million increase in revenue from our license agreement with EBS was primarily due to a $35.5 million increase in net NARCAN® sales in the six months ended June 30, 2021, compared to the six months ended June 30, 2020. The $3.9 million increase in grant and contract revenue was due to the increased funding received from NIDA and BARDA for the development of OPNT003.

For the six months ended June 30, 2021 and June 30, 2020, G&A expenses were approximately $5.4 million.

R&D expenses for the six months ended June 30, 2021, were approximately $7.2 million, as compared to approximately $2.0 million in the comparable period in 2020. External development expense increased by $5.2 million due to increased activity on the Company’s lead product candidate, OPNT003, nasal nalmefene.

S&M expenses for the six months ended June 30, 2021, were approximately $2.0 million compared to approximately $2.8 million in the comparable period in 2020.

Royalty expense for the six months ended June 30, 2021, was approximately $3.1 million, compared to approximately $2.3 million for the comparable period of 2020. The $0.7 million increase was due to increased royalty revenue from the net sale of NARCAN®.

Net loss for the six months ended June 30, 2021, was approximately $1.2 million, or a loss of $0.27 per basic and diluted share, compared to net loss of approximately $1.9 million, or a loss of $0.45 per basic and diluted share, for the comparable period of 2020.

As of June 30, 2021, Opiant had $48.5 million in cash, cash equivalents, and marketable securities.

Opiant is raising its 2021 financial guidance, reflecting higher than expected sales of NARCAN® nasal spray. Aligning its guidance to the upper-range of the full-year 2021 guidance for sales of NARCAN® Nasal Spray provided by EBS, of $325 million, Opiant expects full-year 2021 royalty revenue from the sale of NARCAN® Nasal Spray of approximately $28.9 million. The Company is also updating its guidance for ending cash and now expects to end 2021 with cash, cash equivalents and marketable securities in the range of approximately $42 million to $44 million, not including potential receipt of any additional tranches from the convertible debt deal.

The OPNT003 development project has been funded in part with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract No. HHSO100201800029C.


Conference Call Details:



Thursday, August 5th at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time


Toll Free: 888-394-8218
International: 323-794-2588
Conference ID: 5960603
Webcast: http://ir.opiant.com/


About Opiant Pharmaceuticals, Inc.


Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose.

For more information visit: www.opiant.com.


Forward-Looking Statements


This press release contains forward-looking statements, including anticipated results and timing of the receipt of data from our PD study and timing of filing of an NDA and statements regarding updated royalty revenue guidance and ending cash target in 2021. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements, and among other things, our ability to maintain cash balances and successfully commercialize or partner our product candidates currently under development. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” or “continue” or the negative of such terms and other same terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. Additional factors that could materially affect actual results can be found in our filed quarterly reports on Form 10-Q and our annual report on Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission on March 4, 2021, including under the caption titled “Risk Factors.” These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.

Investor Relations Contacts:

Ben Atkins

VP of Corporate Communications and Investor Relations
[email protected]
(310) 598-5410

      Opiant Pharmaceuticals Inc.                
      Condensed Consolidated Statements of Operations                
      (in thousands, except shares and per share amounts)                
                       
                       
          Three months ended   Three months ended   Six months ended   Six months ended
          June 30   June 30   June 30   June 30
            2021       2020       2021       2020  
          (Unaudited)   (Unaudited)   (Unaudited)   (Unaudited)
Revenues                  
  Royalty revenue     $ 9,314     $ 6,258     $ 13,648     $ 10,456  
  Grant and contract revenue       1,945       55       3,998       139  
    Total Revenue       11,259       6,313       17,646       10,595  
                       
Operating expenses                  
  General and administrative       2,733       2,836       5,380       5,410  
  Research and development       3,150       558       7,238       1,979  
  Sales & marketing       1,023       1,747       2,020       2,823  
  Royalty expense       2,107       1,403       3,086       2,337  
    Total expenses       9,013       6,544       17,724       12,549  
                       
Income (loss) from operations       2,246       (231 )     (78 )     (1,954 )
                       
Other income (expense)                  
  Interest income       4       11       7       88  
  Interest expense       (542 )           (1,079 )      
  Loss on foreign exchange       (24 )     4       (10 )     4  
    Total other income (expense)     (562 )     15       (1,082 )     92  
Income (loss) before provision for income taxes     1,684       (216 )     (1,160 )     (1,862 )
  Income tax expense                         39  
Net income (loss)     $ 1,684     $ (216 )   $ (1,160 )   $ (1,901 )
                       
Other comprehensive income (loss):                
  Foreign currency translation adjustment     (5 )     (17 )     8       (311 )
Comprehensive income (loss)     $ 1,679     $ (233 )   $ (1,152 )   $ (2,212 )
                       
Net income (loss) per common share                
  Basic     $ 0.39     $ (0.05 )   $ (0.27 )   $ (0.45 )
  Diluted     $ 0.31     $ (0.05 )   $ (0.27 )   $ (0.45 )
                       
Weighted-average common shares outstanding:                
  Basic       4,332,601       4,258,105       4,308,027       4,241,423  
  Diluted       5,427,831       4,258,105       4,308,027       4,241,423  
                       

 

      Opiant Pharmaceuticals, Inc.        
      Condensed Consolidated Balance Sheets        
      (in thousands, except shares and per share amounts)        
               
          As of June 30,   As of December 31,
            2021       2020  
Assets     (unaudited)    
  Current assets          
    Cash & cash equivalents     $ 33,443     $ 48,251  
    Marketable securities       15,072        
    Accounts receivable       9,726       8,911  
    Prepaid expenses and other current assets      2,277       1,937  
    Total current assets       60,518       59,099  
  Other assets          
    Property and equipment, net       109       171  
    Right of use assets – operating leases      1,119       279  
    Patents and patent applications, net      12       13  
    Other non-current assets             1,051  
    Total assets     $ 61,758     $ 60,613  
               
Liabilities and stockholders’ equity
       
  Current liabilities          
    Accounts payable and accrued liabilities    $ 2,447     $ 2,966  
    Accrued salaries and wages       891       909  
    Royalty payable       2,107       1,908  
    Deferred revenue             355  
    Operating leases       339       282  
    Total current liabilities       5,784       6,420  
  Long-term liabilities          
    Operating leases       781        
    Convertible debt, net of unamortized discount      18,837       18,701  
    Total long-term liabilities       19,618       18,701  
    Total liabilities       25,402       25,121  
  Stockholders’ equity          
  Common stock, $0.001 par value, 200,000,000 shares         
    authorized, 4,349,599 and 4,258,105 shares         
    issued and outstanding at June 30, 2021         
    and December 31, 2020, respectively      4       4  
  Additional paid-in-capital       102,220       100,204  
  Accumulated other comprehensive loss      (19 )     (27 )
  Accumulated deficit       (65,849 )     (64,689 )
    Total stockholders’ equity       36,356       35,492  
    Total liabilities and stockholders’ equity    $ 61,758     $ 60,613